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Characterizing chromatin interactions is a crucial step towards increasing our understand-
ing of the three-dimensional chromatin. Chromatin spatial organization plays a critical role in
genome functions, such as gene regulation, by allowing distal enhancers to influence the tran-
scription of their target genes.
Most existing methods to detect significant long-range chromatin interactions assume statis-
tical independence between interactions, an assumption which is invalid at high resolution. In
Chapter 2, we present HiC-ACT, an aggregated Cauchy test (ACT) based approach, to improve
the detection of chromatin interactions by post-processing results from methods assuming inde-
pendence. HiC-ACT demonstrates advantages in improving sensitivity with controlled type-I
error. By leveraging information from neighboring chromatin interactions, HiC-ACT enhances
the power to detect interactions with lower signal to noise ratio and similar (if not stronger) epige-
netic signatures that suggest regulatory roles. We further show that the most significant HiC-ACT
peaks overlap with more known enhancers than those from the state-of-the-art Fit-Hi-C/FitHiC2
method.
Existing studies of chromatin conformation have primarily focused on potential enhancers
interacting with gene promoters. By contrast, the interactivity of promoters per se, while equally
critical to understanding transcriptional control, has been largely unexplored. In Chapter 3,
we leverage promoter capture Hi-C data to identify and characterize cell type-specific super-
interactive promoters (SIPs). Notably, promoter-interacting regions (PIRs) of SIPs are more
likely to overlap with cell type-specific ATAC-seq peaks and GWAS variants for relevant blood
cell traits than PIRs of non-SIPs. Further, SIP genes show enriched heritability of relevant blood
iii
cell trait(s). Importantly, this analysis demonstrates the potential of using promoter-centric anal-
yses of chromatin spatial organization data to identify biologically important genes and their
regulatory regions.
As over 90% of GWAS variants lie in non-coding DNA, it is challenging to identify the
causal variants, although critical to understanding genetic mechanisms underlying diseases. Chap-
ter 4 proposes MARVIN (Multi-disease/trait Annotation of Regulatory Variants using Integrated
Networks), a method to predict the impact of non-coding regulatory variants on effector genes
relevant to groups of diseases/traits at varying resolution. By constructing disease-specific gene
regulatory networks and simultaneously modeling related diseases, MARVIN has increased
power to accurately predict causal variants.
iv
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CHAPTER 1: LITERATURE REVIEW
1.1 Genome-Wide Association Studies (GWAS)
Genome-wide association studies (GWAS) are systematic surveys that investigate the asso-
ciation between common genetic variants and complex diseases or traits [13]. GWAS relies on
linkage disequilibrium (LD) between genotyped single nucleotide polymorphisms (SNPs) and
ungenotyped causal variants [129]. LD refers to the non-random association of alleles at two or
more loci [119]. In general, LD is stronger for physically close loci, compared to distant loci, and
decays exponentially with distance [129]. Consequently, GWAS is better powered to detect as-
sociation with common variants (minor allele frequency ą 0.05) rather than rare variants (minor
allele frequency ă 0.01) [3].
GWAS aims to understand disease mechanism and has been successful in identifying nu-
merous trait- and disease-associated genetic variants, including genomic loci associated with
body mass index (BMI), bone mineral density (BMD), fasting-glucose, cardiovascular disease,
inflammatory bowel disease, type 2 diabetes, and breast cancer [13, 62, 70, 84, 90, 129]. Methods
developed for GWAS can also be applied to analyze expression quantitative trait loci (eQTL) and
establish targets for novel therapies [88, 90]. A large collection of published human GWAS (ą
4,000 publications) is freely available through the NHGRI-EBI GWAS Catalog [13].
Over 90% of GWAS identified variants lie in non-coding DNA [88]. A proportion of these
variants have been discovered in or near cis-regulatory elements, and evidence suggests that
they may contribute to disease pathogenesis by affecting the regulatory mechanisms of gene
transcription [62, 84, 88]. It has been demonstrated that high resolution 3D genome-wide analy-
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sis (chromosome conformation capture) has the ability to annotate GWAS SNPs and link these
GWAS variants to their target genes, which are potentially disease-causing [65, 136, 146].
1.2 Cis-Regulatory Elements
Gene expression is regulated through the integrated action of typically non-coding DNA
regions known as cis-regulatory elements (CREs) [121, 135]. Key CREs include promoters,
enhancers, silencers, and insulators, though promoters and enhancers are the best understood
[75, 135]. Millions of potential cis-regulatory elements have been discovered in the genome
and cataloged by, for example, ENCODE Project Consortium [29, 21], Roadmap Epigenomics
Consortium [26], and Yue et al. 2014 [147].
Promoter sequences are located immediately upstream of a gene surrounding the transcrip-
tion start site (TSS) and initiate gene transcription [68, 70, 135]. Promoters alone only produce
basal levels of mRNA, and thus require enhancers to activate or increase the rate of transcription
[68].
Enhancers are DNA sequence modules (varying in size but typically spanning approximately
a few hundred base pairs) that are binding sites for specific sets of transcription factors [5, 70,
116]. Enhancer activity is independent of the orientation and position relative to the target genes
[68]. The distinct chromatin signature of enhancers is described by transcription factor binding,
which often includes increased DNA accessibility and an accumulation of the histone marks
H3K4me1 and H3K27ac [61, 70, 116, 121]. These characteristics are frequently used to label
genomic sequences as potential enhancers [70]. In addition, enhancer activity is largely cell type-
specific and tens of thousands of enhancers may be active in any one cell type [60, 61, 128, 133].
A large proportion of enhancers reside in intergenic regions up to megabase (Mb) away from the
promoters of their target gene [21, 79, 26, 111, 112, 147, 147].
Clusters of transcriptional enhancers close in linear genomic proximity that reach high
thresholds for the binding density of key transcription factors are known as super-enhancers
[70, 133]. Super-enhancers are larger (often kilobases in size) and have greater transcription fac-
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tory density and content than typical enhancers. It has been demonstrated that super-enhancers
drive cell type-specific gene expression programs [63, 133]. Further, evidence suggests that super-
enhancers of disease-relevant cell types are enriched for disease-associated variation, lending to
the important role that super-enhancers have in cell identity and disease [61, 63].
1.3 3D Chromosomal Organization
The entire genome of DNA sequences must be significantly packed to fit into the confined
cell nucleus [96]. Recent evidence suggests that chromatin fibers are not folded in a hierarchical
order, but rather are compacted in different densities with various conformations [78, 99]. Al-
though the exact mechanisms are unknown, it is believed that the chromatin polymer structure
determines DNA accessibilities and gene regulation [8, 28, 78, 91].
Chromatin fiber loops joining enhancers and promoters allow for distal enhancers to influ-
ence the transcription of their target genes, many of which are not their immediate neighbors (i.e.,
gene expression is largely dependent on chromatin folding) [31, 91, 97, 109, 111, 116]. Chro-
matin loops joining insulator elements may be responsible for creating segregated chromatin
domains, which in turn, restricts enhancer activity [102, 146]. The precise mechanisms by which
chromatin interactions are formed and maintained are still unknown.
Due to the abundance of enhancer elements and their long-range regulation, systematic map-
ping of enhancer-promoter interactions is challenging [78]. In addition, many distal enhancers
reside in the non-coding portion of the genome [128]. However, understanding these interactions
is crucial to discovering the functional effects of disease-associated mutations and chromosomal
rearrangements [70]. Moreover, knowledge of the 3D chromatin structure in various cell types
and developmental stages can aid in linking enhancers with their target genes [146].
Various imaging techniques, such as FISH (fluorescence in situ hybridization), have been
used to study chromosome organization within the nucleus [10, 33]. Imaging approaches have
revealed chromosome territories as well as provided insight into sub-nuclear structures and tran-
scription, suggesting the nucleus is spatially and functionally compartmentalized [33, 97]. How-
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ever, imaging is unable to map chromosome folding genome-wide and at sufficient resolution
necessary for observing individual genes and regulatory elements. Numerous technologies have
been developed in recent years, such as chromosome conformation capture (3C) [32] and its
derivatives, to overcome these limitations of imaging techniques and perform a comprehensive
genome-wide analysis of 3D genome organization [146].
1.4 Chromosome Conformation Capture (3C)
Chromosome conformation capture (3C) technologies are used to study the overall spatial
organization of chromosomes. Briefly, 3C begins with chemical cross-linking genomic DNA to
capture the 3D interactions within the cell (i.e., linking chromatin segments spatially close in the
nucleus). Next, the chromatin is digested with a restriction enzyme, such as HindIII, producing
DNA fragments that are then ligated. After reversing the cross-links, individual ligation products
can be detected and quantified by polymerase chain reaction (PCR) using locus-specific primers.
Thus, 3C generates a single interaction profile for a selected set of genomic loci (i.e., quantifies
the contact frequency between two preselected loci) [32, 97].
Analysis of pairwise contact frequencies provides insight into the physical properties and
folding of chromosomes, as well as their overall spatial organization [32]. In that regard, 3D
genome organization can be successfully inferred with sufficient pairwise contact frequencies
[33, 146]. However, 3C is limited by locus-specific PRC (“one-versus-one” analysis), and con-
sequently is focused on detecting looping interactions in relatively small regions (10Kb-1Mb)
[97]. Accordingly, several technologies have been derived from 3C, including 4C (3C-on-chip)
[117, 150], 5C (3C-Carbon Copy) [35], and Hi-C, that seek to increase the throughput of the
assay.
Following ligation, 4C employs inverse PCR with primers on the fragment of interest to
achieve “one-versus-some” [7, 117, 150]. Through multiplexed ligation-mediated amplification,
5C expands the interaction profile to “many-versus-many” [7, 35]. Unlike most 3C-based tech-
niques that require a set of target loci for analysis, Hi-C considers the interactions of all genome-
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wide loci, enabling “all-versus-all” interaction profiling and unbiased identification of long range
chromatin interactions across the genome [7]. It is important to note that while 3C-based assays
profile genomic loci interactions, they do not assess functionality or co-localization mechanisms
[33].
1.4.1 Hi-C Technology
Akin to other 3C-based methods, Hi-C begins with cross-linking cells with formaldehyde,
creating covalent DNA-protein binding between spatially adjacent chromatin segments. The
DNA is digested with a restriction enzyme (HindIII), leaving a 5’ restriction fragment overhangs.
As the 5’-overhangs are filled in, the DNA ends are marked with biotinylated nucleotides. This
step is Hi-C-specific and critical to successful deep sequencing of all ligation junctions. Next,
the blunt-end fragments are ligated under conditions that favor ligation events between cross-
linked DNA fragments. This produces a genome-wide collection of ligation products that were
originally in close proximity to each other in the nucleus and whose junction site is marked with
biotin. Subsequently, the DNA is purified and sheared, and the biotinylated junctions are iso-
lated using streptavidin beads. At this stage, the DNA junctions are ready for high-throughput
sequencing. Paired-end sequencing of this data creates a Hi-C library of interacting fragments
[79, 127].
1.4.1.1 Mapping
The sequenced Hi-C library then undergoes read mapping and filtering. A short read se-
quence alignment algorithm, such as Bowtie or Maq, maps the sequenced Hi-C reads to the
genome. The types of molecules present can be described by the orientation of the mapped reads
relative to restriction sites. Two mapped reads occurring on the same restriction fragment indicate
either a self-circularized ligation product (if the reads face outward) or an un-ligated “dangling
end” product (if the reads face inward). These same-fragment pairs should not exceed 0.5-5%
and 10-45%, respectively, of a successful Hi-C library and are removed. In contrast, two mapped
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reads occurring on different restriction fragments and facing toward a restriction site indicate a
valid interaction pair (true ligation product). Valid pairs with redundant PRC artifacts should not
exceed 5% of a successful Hi-C library and are filtered out. Hi-C libraries with large proportions
of invalid interaction pairs signal potential issues during the library preparation protocol [7, 73].
1.4.1.2 Binning
Due to the vast number of possible restriction fragment interactions (on the order of 1011
in the human genome) and the difficulty of achieving sufficient sequencing depth to cover all
of the interactions well, Hi-C libraries are typically binned into fixed interval sizes (i.e., 5Kb,
10Kb, 40Kb, . . . , 1MB). For each chromosome, the Hi-C data is divided into consecutive non-
overlapping regions by the specified bin size. Binning aggregates the interaction counts within
the interval/bin, effectively reducing the complexity of the data and increasing the coverage and
statistical power [7, 73]. There is an inverse relationship between bin size and data resolution – as
bin size increases, discriminatory power is gained while resolution is lost [7]. High resolution Hi-
C has a high sequencing cost, requiring 2 billion and 6.5 billion total reads to achieve 10Kb and
1Kb resolution, respectively [79, 102, 146]. However, low data resolution with low sequencing
depth can lead to unreliable results.
1.4.1.3 Bias Correction/Normalization
The Hi-C data is summarized by a genome-wide symmetric contact matrix M, where each
entry mij corresponds to the number of interactions between locus i and locus j [73, 79]. The fi-
nal step in preparing Hi-C data for analysis is to perform bias correction/normalization. Biases in
Hi-C data can arise from differing mappability, GC content, and fragment length across genomic
bins. Explicit bias models attempt to directly use these features, whereas implicit bias models
use balancing (equalizing the sums of counts across each bin in the genome) [7, 73]. To account
for the effect of genomic distance between pairs of loci, each mij entry is divided by the genome-
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wide average contact probability for loci at that genomic distance, resulting normalized matrix
M˚ [79, 127].
1.4.1.4 Contact Matrix
A heatmap is often used to visualize the contact matrix, with each pixel representing the in-
teraction frequency between pairwise loci. Genome-level trends are observed in a Hi-C heatmap.
Pairs of loci that reside on the same chromosome have a higher interaction frequency on aver-
age compared to pairs of loci that reside on difference chromosomes (i.e., cis-interactions have
higher interaction frequencies than trans-interactions). This trend is reflected by large square
blocks of heightened signal, representing individual chromosomes, on the main diagonal of a
genome-wide interaction heatmap [73]. Additionally, DNA fragments in close proximity in the
linear genome tend to interact frequently with each other, which is seen through a strong signal
along the heatmap’s diagonal that dissipates as the distance increases (i.e., as the pairs under
study move further away from the diagonal) [7, 127]. Moreover, the thickness of the diagonal
represents the compactness of the chromatin along the chromosome [7].
Nearby loci are likely to share neighbors, and therefore, have correlated interaction profiles.
Using the normalized contact matrix M˚, a correlation matrix C can be computed where each
cij entry corresponds to the Pearson correlation between the ith row and jth column of M˚ [79].
Visualizing C as a heatmap reveals a strong ‘plaid’ pattern, suggesting compartmentalization of
the genome into regions of enriched and depleted interactions (active and inactive chromatin)[7,
79, 127]. Principle-component analysis shows that the first principal component corresponds to
the partitions of each chromosome into the two compartments [79].
1.4.2 General Features of 3D Genome Organization
Genome-wide 3C techniques, such as Hi-C, reflect general features of 3D genome organi-
zation, including compartments, topologically associating domains (TADs), chromatin loops,
and long-range chromatin interactions [73, 102, 146]. Evidence suggests that genomic compart-
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ments and long-range chromatin interactions exhibit some cell-type specificity, while TADs and
chromatin loops are preserved across cell types [33, 146].
1.4.2.1 Genomic Compartments
Genomic compartments are the largest-scale, position-specific interaction feature observed in
Hi-C data. As mentioned in the previous section, the genome can be categorized by two com-
partments, termed A and B, representing high and low interaction frequencies, respectively
[7, 73, 79, 102, 127]. These A/B compartments/blocks alternate along the chromosome and span
„1-10Mb. Further, genomic compartments are correlated with transcriptional activity, includ-
ing DNA accessibility, gene density, replication timing, GC content, and histone marks. Com-
partment A is euchromatic, gene-dense, and associated with active chromatin state, whereas
compartment B is heterochromatic and gene-poor [33, 73, 79, 146]. It has also been shown that
compartments preferentially interact with compartments of their type (i.e., A with A) and occupy
different spatial compartments in the nucleus [33, 79].
1.4.2.2 Topologically Associating Domains
Chromosomes are composed of topologically associating domains (TADs), which cover over
90% of human and mouse genomes [33]. Compared to genomic compartments, TADs are smaller
(sub-Mb structures), can be active or inactive, and adjacent TADs are not necessarily of opposite
chromatin status [33, 73]. In this way, adjacent TADs can organize within A and B compartments
[33, 102]. Genomic loci within the same TAD have severalfold higher contact frequency than
do loci belonging to different TADs [33, 73, 146]. Given pairs of loci with similar genomic dis-
tances, a loci pair from the same TAD is spatially closer than a loci pair from different TADs
[146]. TADs are observed on an interaction heatmap as square blocks of heightened interaction
frequency centered along the diagonal.
TADs are defined by their boundaries. One approach to define TAD boundaries transforms
the difference between each bin’s average upstream and downstream interactions into a chi-
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squared statistic, referred to as the directionality index, which should change sharply at TAD
boundaries. A Hidden Markov Model is then used to associate the boundaries and infer the loca-
tions of TADs [34].
Evidence suggests that TADs are a fundamental unit of genome organization and are asso-
ciated with gene-regulatory features [34, 73, 146]. Specifically, TAD boundaries are enriched
for CTCF binding sites and housekeeping genes [34, 146]. TADs may also restrict long-range
interactions between genes and regulatory elements [32, 78].
1.4.2.3 Long-Range Chromatin Interactions
Chromatin loops are believed to play an important role in transcription control by bringing
pairs of linearly distant genomic loci into close spatial proximity within the nucleus. Of course,
a large portion of observed contacts are seemingly due to random polymer looping. On the other
hand, the biologically-driven looping interactions frequently involve active promoters, enhancers,
and CTCF binding sites. Among these loops, those mediated by the binding protein CTCF, dis-
tinguish TAD boundaries and tend to be invariant across cell types. A second type of interaction
is formed by specific chromatin loops between enhancer and promoter sequences and are cell
type-specific [33, 102, 146]. Studying 3D genome structure and cell type-specific transcriptional
regulation is motivated by these regulatory chromatin loops which coordinate gene regulation
[78]. Functional intra-chromosomal contacts/interactions will be the focus of this paper.
1.4.3 Peak Calling Methods
Due to the potential regulatory nature of chromatin loops and the drive to better understand
the 3D genome structure, there is significant interest in discriminating between functional con-
tacts and contacts due to random looping. Consequently, several methods exist to determine if
the observed chromatin interaction frequency is significantly higher than expected from random
ligation. Such methods are often referred to as “peak callers”, where “peaks” refer to statistically
significant chromatin interactions.
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Fit-Hi-C [4] is a popular software tool to evaluate all chromatin loci pair independently, and
assign each loci pair a statistical confidence (p-value). Fit-Hi-C corrects for distance dependence
and potential systematic biases in Hi-C datasets by fitting non-parametric splines to model the
background chromatin contact frequency [4, 67]. Recently, a re-implementation, FitHiC2 [67],
was released. Along with the addition of new computational modules, FitHiC2 can be run on the
highest-resolution Hi-C datasets currently available. However, in high-resolution data (e.g., 5Kb
or 10Kb bin resolution), neighboring chromatin interactions are unlikely to be independent, as as-
sumed in FitHiC2. When this independence assumption is violated, the p-values corresponding to
chromatin interactions are inaccurate as loci are more likely to interact with each other if adjacent
loci exhibit high interaction frequency [141].
Hidden Markov random field (HMRF) based methods such as HMRFBayes [141] and
FastHiC [140] accommodate spatial dependency for improved statistical properties. These
HMRF methods are similar to the hidden Markov model (HMM) and the hidden Ising model
for peak identification from ChIP-Seq data. HMRFBayes models the loci dependency and explic-
itly borrows information from neighboring fragment pairs [141]. Though HMRFBayes shows
improved performance over Fit-Hi-C, the underlying Bayesian framework is computationally
intensive [141, 140]. Accordingly, FastHiC was developed to improve upon the HMRF-Bayes
model, in both computational time and peak calling accuracy. Rather than assume that the hid-
den peak status follows an Isling distribution as in HMRFBayes, FastHiC approximates the joint
distribution of the hidden peak status by using a set of independent random variables to get a
modified pseudo-likelihood [141].
HiCCUPS [102] (Hi-C Computational Unbiased Peak Search) is another commonly adopted
method for identifying significant chromatin interactions. Unlike Fit-Hi-C/FitHiC2 and the
HMRF based methods which use a global background model [4, 67, 141], HiCCUPS uses a
local background model where each chromatin loci pair has a unique model influenced by in-
formation from local neighborhoods [102]. This model defines peaks based on whether the loci
pair interacts significantly more than loci pairs in its neighborhood. Therefore, HiCCUPS effec-
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tively detects summits of chromatin interactions, rather than peaks as in Fit-Hi-C/FitHiC2 and the
HMRF based methods. A most recently published method, MUSTACHE, similarly relies on a lo-
cal background model and detects summits using a scale-space modeling framework enlightened
by methods in computer vision [106]. The summit-detection strategy is valuable in distinguish-
ing the most frequently interacting pairs from its neighborhood, but limits its ability to identify
many functionally important within-domain interactions that link regulatory elements such as
enhancers and promoters to each other [67]. For example, FitHiC2 reports capturing 13,502
out of 17,023 enhancer interactions (within the distance range of 15Kb-1Mb) predicted by the
activity-by-contact (ABC) model [45], while HiCCUPs only captures 1,667 of these interactions
[67].
1.4.4 Promoter Capture Hi-C (pcHi-C)
Genome-wide chromosome conformation capture techniques such as Hi-C have been widely
used to study 3D organizations of chromatin and map distal regulatory regions to their target
genes. However, due to the complexity and sparsity of Hi-C data, it is difficult to identify statis-
tically significant chromatin interactions between distant genomic sequences at fine resolutions
(e.g, at restriction fragment level, or ă 10Kb equal size bin level) even with tens of billions of
pairwise reads produced [114]. Further, ultra-deep sequencing is costly and likely to generate
redundant reads, leading to Hi-C library saturation [73]. In addition, chromatin spatial organiza-
tion studies have largely focused on regulatory regions. By contrast, promoter regions have been
largely taken for granted and automatically removed from under the spotlight.
To bridge this gap, Promoter Capture Hi-C (pcHi-C) was developed as an extension of the
Hi-C technique by combining target enrichment and sequencing. pcHi-C is specifically enriched
for promoter sequences and enables the genome-wide detection of distal promoter-interacting
regions (PIRs), for all promoters with a priori designed probes/baits in a single experiment [114].
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1.4.4.1 pcHi-C Technology
Promoter Capture Hi-C begins with generating Hi-C libraries using in-nucleus ligation, fol-
lowed by in-solution hybridization with tens of thousands of biotinylated RNA baits targeting all
promoter restriction fragments containing HindIII. Next, ligation products between promoter-
containing restriction fragments and their interacting restriction fragments are captured on
streptavidin-coated magnetic beads and isolated. Paired-end sequencing is then executed, and
the resulting pcHi-C library is processed using the HiCUP pipeline [134] to perform mapping,
filtering, and quality control [114].
In-nucleus ligation significantly reduces trans-paired-end sequence reads, which only com-
prise 5-25% of a successful pcHi-C library. Consequently, this reduces the complexity of a pcHi-
C library compared to the original Hi-C library. In this way, pcHi-C is able to focus on identi-
fying significantly high interaction frequencies of fragments that are ligated to promoters. A
majority (70-90%) of pcHi-C ligation products are paired-end sequence reads between two non-
adjacent restriction fragments. pcHi-C libraries have a greater percentage of these valid pairs
than corresponding Hi-C libraries. Moreover, pcHi-C libraries show „15-fold enrichment for
promoter-containing ligation projects (i.e., reads between a captured promoter fragment and a
second captured promoter fragment or a HindIII non-promoter restriction fragment) over Hi-C
libraries [114].
1.4.4.2 Promoter Interactome Maps
The resulting promoter interactome maps are a collection of long-range interactions be-
tween the captured promoter fragments and promoter-interacting regions (PIRs). The CHiCAGO
pipeline [15] can be used to identify high-confidence interactions. CHiCAGO (Capture Hi-C
Analysis of Genomic Organization) assigns confidence scores to interactions based on the as-
sumption that significant interactions emerge as outliers on a distance-dependent local back-
ground model [15].
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Evidence suggests that promoter interactomes are associated with gene expression control.
PIRs interacting with promoters of highly expressed genes show enrichment in enhancer marks,
such as H3K27ac [65, 92, 113, 114]. However, only a small proportion of PIRs thought to con-
tain regulatory modules are enhancers. The other PIRs may not have direct transcriptional regu-
latory functions or they simply may not exhibit classic enhancer marks. Another group of PIRs
may be associated with transcriptional repression H3K27ac [92, 114].
Promoter interactomes (the set of all interactions involving promoters within a cell) are
tissue- and lineage-specific and have been used to link promoters to GWAS risk loci [65, 92, 113,
114]. Consequently, there has been growing interest in studying cell type-specific differences in
PIRs. As one example, pcHi-C analysis of 17 human hematopoietic cells demonstrated that PIRs
are highly cell type-specific and reflective of the expected lineage relationships (such as mapping
of promoter interactions for T-cell receptor component encoding genes to lymphoid cell types
only, not to myeloid lineage cell types). Importantly, this analysis demonstrated the ability of
pcHi-C to link non-coding regulatory variants to their target genes [65]. Thus, pcHi-C analysis
can be leveraged to provide insight into gene expression control and the function of non-coding
disease-associated sequence variants [114].
A recent study on human corticogenesis has identified a subset of promoters exhibiting un-
usually high degrees of chromatin interactivity (where chromatin interactivity is defined by cu-
mulative CHiCAGO[15] scores of interactions with neighboring regions), which were termed
super-interactive promoters (SIPs) [120]. Song et al. found that these brain cortex SIPs were en-
riched for corresponding lineage-specific genes, suggesting that the interactions between SIPs
and their regulatory networks may play a role in modulating cell type-specific transcription. In
addition, Song et al. also found SIPs in hematopoietic lineages using pcHi-C data, but did not
perform further annotation or characterization of these hematopoietic SIPs.
13
1.5 Predicting Enhancer-Promoter Interactions
Enhancers and promoters are two major cis-regulatory elements (CREs) that control context-
dependent gene transcription. Consequently, there is significant interest in detecting and verifying
functional enhancer-promoter interactions (EPIs). However, the complexity of EPI formation
and undefined determinants linking functional enhancer-promoter pairs limit accurate detection
of functional EPIs in a high throughput manner. For example, in the human genome, there are
millions of candidate enhancers and only „20,000 genes, complicating the detection of tissue/-
cell type-specific EPIs [21, 26, 139]. Moreover, only 40% of enhancers can regulate their nearest
gene, while many can regulate genes which are far away in one-dimensional (1D) genomic dis-
tance from their target genes (e.g., up to Mb away) [1, 44, 78, 87, 146]. Importantly, EPIs do not
imply functional causation.
By definition, a functional EPI requires active status of enhancers and promoters, spatial
proximity between enhancers and promoters, and context-dependent gene expression alteration
(i.e., positive transcription outcome) [139]. Therefore, a key component of functional EPI detec-
tion is to investigate whether the associated CREs are activated in particular conditions. Many
techniques exist for defining active CREs (e.g., using histone marks or transcription factor (TF)
binding), but they do not provide direct evidence for linkage between enhancers and promoters
[38, 139]. Importantly, CRE activation does not necessarily imply a truly functional EPI. Another
critical property of a functional EPI is spatial adjacency of the corresponding enhancer and pro-
moter (by chromatin loop formation). As discussed earlier, chromatin loops can be identified
through chromosome conformation capture (3C) derived techniques [46, 94, 97, 102]. These
chromatin loops identified by 3C data could either be functional loops, structural interactions, or
interactions by chance.
It follows that a common practice for detecting EPIs is to overlap tissue/cell type-specific
active CREs with high resolution chromatin interactions [139]. However, a majority of Hi-C
maps are at 10-40Kb resolution and high resolution genome-wide chromatin loop data are only
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available for limited human tissues/cell types [131]. To predict unseen EPIs at different contexts,
many computational methods have been developed by learning or modeling existing 3D genomic
data and other molecular phenotype profiles.
1.5.1 Unsupervised Learning Methods
There are two main classes of methods for predicting EPIs – unsupervised learning meth-
ods and supervised learning methods. Unsupervised learning methods include distance-based
methods, correlation-based methods, and decomposition-based methods.
Distance-based methods, such as PreSTIGE [27] and ABC [45], identify EPIs by linking
enhancers to the nearest promoter. PreSTIGE links cell type-specific enhancers (using H3K4me
marks as enhancer signals) to cell type-specifically expressed genes. The activity-by-contact
(ABC) model scores the potential of an EPI by combining distance effect and enhancer activity.
Some distance-based methods restrict the regulatory scope of enhancers to within specific 3D
genome architectures, such as TADs or insulated neighborhoods, to improve the false positive
rate [139]. However, this approach, and distance-based methods in general, hardly consider long
distance interactions; as mentioned previously, many enhancers do not regulate their nearest
genes. Further, these methods are highly dependent on accurate identification of cell type-specific
regulatory elements.
Correlation-based methods detect EPIs by computing the correlation of epigenomic marks
between enhancers and promoters from a panel of samples. Many such methods exist that utilize
various chromatin features and algorithms to compute the correlation. Recent correlation-based
methods include: ELMER [144, 145] (Pearson’s correlation between DNA methylation and
RNA-seq), Cicero [101] (Graphical LASSO with single-cell ATAC-seq), and C3D [89] (Pear-
son’s correlation between DNase I hypersensitivity signals across many cell types). Correlation-
based methods generally outperform distance-based methods, but require a large panel of sam-
ples and are influenced by the choice of chromatin features and correlation algorithm. For in-
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stance, methods using Pearson’s correlation tend to be sensitive to outliers and have increased
false positive prediction [101].
Decomposition-based methods, such as EpiTensor [151]and TransDecomp [104], leverage
multiscale information from omics data to capture spatial features of the genome and predict
EPIs. EpiTensor first combines epigenomic data from 18 assays in five cell types as a third-order
tensor, then uses tensor decomposition to decompose into three subspaces: cell type, assay, and
genomic locus. Since the genomic locus subspace is associated with 3D interactions among reg-
ulatory elements, EPIs can be inferred by linking the eigenvector peaks of the locus subspace us-
ing distance-based approaches. TransDecomp takes a different approach, and first uses transcrip-
tional decomposition to decompose CAGE signals into two principle components, separating the
component of expression that reflects the positional relationship between neighboring genomic
regions (positional dependent) and the component of expression dictated by transcriptional unit’s
individual regulatory programs (positional independent). TransDecomp then trains a random for-
est classifier using features related to the components to identify EPIs in promoter-capture Hi-C
data.
1.5.2 Supervised Learning Methods
The second class of EPI prediction methods involves supervised learning methods, includ-
ing training classifiers with machine learning and regression based methods. Numerous training
classifiers have been proposed to distinguish EPIs from random negatives. Training is done using
either a machine learning approach (e.g., random forest, logistic regression, or support vector
machine (SVM)) or a deep learning approach (e.g., convolutional neural network (CNN) or recur-
rent neural network to extract features before implementing a machine learning approach) [139].
As an example, IM-PET [59] first predicts enhancers from ChiP-seq data using CSI-ANN [41],
then computes four feature scores separately for each enhancer-candidate promoter pair. These
four features encompass aspects of methods discussed previously, and include: distance between
enhancer and promoter, enhancer-promoter activity correlation profile, correlation between tran-
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scription factor and promoter, and coevolution of enhancer and promoter. IM-PET integrates
these features using random forest to classify EPIs. Some methods, including RIPPLE [107] and
TargetFinder [132], directly use omic profiles to train classifiers and achieved high performance
in EPI identification within specific cell types, but require too many features to practically expand
these models to many tissues/cell types. Other cell type-specific EPI detection methods only use
DNA sequence features (e.g., SPEID [118], EPIANN [86], PEP [143], and EP2vec [148]). Fi-
nally, training classifiers can be constructed using open chromatin profiles for cell type-specific
signatures (e.g., McEnhancer [56], Rambutan [115], and DeepTACT [76]). For any training clas-
sifier, it is important to properly generate the training dataset and have an unbiased sampling
procedure. Training classifiers are limited by their inability to estimate regulatory potential and
may also struggle with feature selection [139].
Unlike training classifiers, regression-based methods can evaluate regulatory potential by
directly associating CREs with gene transcription. One such method, FOCS [57], employs leave-
cell-type-out cross validation as it trains a regression model to estimate the level of promoter
activity (independent variable) from the levels of its k closest enhancers (dependent variables).
Agreement between predicted and observed promoter levels is then tested, followed by BY-FDR
p-value correction, and fitting the full regression models using all samples for promoters passing
the validation tests. FOCS lastly uses elastic net to select the most important enhancers, produc-
ing cross-validated optimally-reduced EPIs. CT-FOCS [58] extends this methodology to infer
cell type-specific EPI by using multiple replicates per cell type.
1.6 Predicting Causal Non-Coding Risk Variants
As previously discussed in Section 1.1, most variants associated with human disease lie
in non-coding genomic regions, making it difficult to directly evaluate functional impact. To
address this challenge, several computational methods have been developed to prioritize causal
non-coding risk variants through integrating various genomic and epigenomic annotations (e.g.,
CADD [69], GWAVA [105], and FunSeq2 [43]). Importantly, these methods do not account
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for the interactions, for example, between transcription factors and their target genes or among
target genes in the same pathway, despite disease-perturbed gene networks being vital to the
development of disease. However, it has been demonstrated that inference accuracy of causal
coding variants can be improved by using molecular networks [64, 74, 149]. Further, network
biology has proven to be a powerful tool for representing and analyzing the complex molecular
networks during pathogenesis [6, 17, 100, 108]. Since the effects of non-coding variants are
transcriptionally integrated in a regulatory network, a network-based approach is an effective
strategy to identify causal non-coding variants [50, 98]. Moreover, previous studies have reported
enrichment of GWAS SNPs in tissue/cell type-specific regulatory sequences [39, 88], lending to
the importance of constructing disease-relevant tissue/cell type-specific gene regulatory networks
(GRNs).
A recently developed network-based approach, ARVIN (Annotation of Regulatory Variants
using Integrated Networks) combines sequence-based and network-based features to provide a
computational framework for predicting causal non-coding variants in a disease/trait-specific
context [50]. For each disease, ARVIN first constructs an integrative GRN. The network con-
sists of two types of nodes (genes and SNPs/variants) as well as two types of edges (gene-gene
interactions (functional interaction [FI] edge) and SNP-gene interactions (enhancer-promoter
[EP] edge)). Here, SNPs of interest are determined by the intersection of a lead GWAS SNP’s
LD block with a set of enhancers from disease-relevant tissue/cell types. FI edges are taken from
HumanNet [74], a functional gene network of protein coding genes in humans. EP edges are
based on enhancer-promoter interactions predicted by the IM-PET algorithm [59] (briefly pre-
sented in Section 1.5.2) using tissue/cell type-specific ChIP-seq and gene expression data. Using
these nodes and edges, five network-based features are calculated that are designed to evaluate
the topological importance of the target genes. ARVIN incorporates these network-based fea-
tures with sequence-based features used by GWAVA [105] and FunSeq2 [43] (182 genomic and
epigenomic features in total) to train a random forest classifier for predicting risk variants. Conse-
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quently, probability scores for a set of SNPs can be obtained from the trained model to prioritize
risk variants.
Gao et al. provide compelling evidence for incorporating disease-specific network-based fea-
tures with sequence-based features to identify causal non-coding variants. First, they demonstrate
that network features can distinguish true risk SNPs from control SNPs. Moreover, they show
disease-specific networks have more discriminative power than non-disease-specific networks in
distinguishing true risk SNPs from control SNPs. Although network-based features alone are in-
formative, highest accuracy in predicting causal non-coding mutations is resultant of integrating
both network- and sequence-based features (ARVIN outperforms GWAVA and FunSeq2, which
only use sequence-based features). Thus, the performance of ARVIN suggests that features de-
rived from integrative disease-specific GRNs are complementary to sequence-based features, and
can be used to significantly improve the inference accuracy of non-coding risk variants [50].
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CHAPTER 2: HIC-ACT: IMPROVED DETECTION OF CHROMATIN INTERACTIONS
FROM HI-C DATA VIA AGGREGATED CAUCHY TEST
2.1 Introduction
As previously discussed in Section 1.4.3, there is significant interest in determining if chro-
matin interactions are functional contacts or contacts due to random looping. Further, peak call-
ing methods such as FitHiC2 [4, 67] assume neighboring chromatin interactions are independent,
which is unlikely in high-resolution data (e.g., 5Kb or 10Kb bin resolution). It has been shown
that spatial dependency is non-negligible when analyzing Hi-C data at high resolution [141].
When this independence assumption is violated, the p-values corresponding to chromatin interac-
tions are inaccurate.
In this chapter, we develop HiC-ACT, a method for post-processing peak calling results from
methods that do not consider spatial dependency. HiC-ACT’s post-processing via an aggregated
Cauchy test approach accounts for possible correlation between adjacent loci pairs from high res-
olution Hi-C data. HiC-ACT, a summary statistics-based approach, is flexible in application, only
requiring the input of bin identifiers and corresponding raw p-values generated from established
3D peak callers rather than raw Hi-C data. HiC-ACT also allows users to specify a smoothing
parameter based on the data resolution. Moreover, HiC-ACT does not require any information
about the underlying correlation structure in the data while being able to account for the inherent
correlation between bin (loci) pairs.
The implementation of p-value smoothing in HiC-ACT improves identification of significant
chromatin interactions and recovers information lost in sparse data. Since HiC-ACT borrows
information from neighboring loci pairs, it calls peaks rather than summits. Thus, we chose to
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compare HiC-ACT to FitHiC2. Both simulation studies and real data analyses demonstrate that
HiC-ACT outperforms FitHiC2 in increasing recall with comparable precision.
In the remainder of this chapter, we specify the HiC-ACT model and provide details regard-
ing the workflow. Next, we show real data-based simulation results based on Hi-C data from
the human lymphoblastoid cell line GM12878 at various sequencing depths. Then, we perform
real data analysis using Hi-C datasets from GM12878 and mouse embryonic stem cells (mESC).
Finally, we conclude with some discussions.
2.2 Methods
2.2.1 Aggregated Cauchy Test
HiC-ACT is based on the aggregated Cauchy test [82] to combine a set of p-values p1, p2, . . . , pk.





wi tantp0.5´ piqπu (2.1)
where pi is the individual p-value, wi is the non-negative weight such that
řk
i“1wi “ 1, and k is
the total number of p-values to be combined. When only one p-value is considered (k “ 1), it is
straightforward to show that T follows a Cauchy distribution (location parameter x0 “ 0, scale
parameter γ “ w1 “ 1) under the null hypothesis that p1 is uniformly distributed between 0 and
1 [82]. Liu and Xie showed that this combination of p-values, T , follows a standard Cauchy dis-
tribution (x0 “ 0, γ “ 1) under the null hypothesis [82]. Assume that the p-values are calculated
from Z-scores and let X “ pX1, X2, . . . , XkqT , where Xi is a test statistic corresponding to pi.
The null hypothesis can then be written as H0: ErXs “ 0.





wi tantp2Φp|Xi|q ´ 1.5qπu (2.2)
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If the pi’s are perfectly dependent (i.e., all the pi’s are equal or linear functions of one an-
other) or perfectly independent, then it can be shown that the sum of multiple independent
Cauchy random variables also follows a Cauchy distribution. Furthermore, it has been shown
that this holds even when the pi’s are correlated [82, 83].
Liu et al. further showed that under arbitrary dependency structures, T pXq has approximately
a Cauchy tail [82, 83]. They also demonstrated that when the pi’s are correlated, it has very lim-
ited effect on the tail of the distribution. Consequently, we can transform the test statistic T back








Because of the heavy tail of the Cauchy distribution, T is insensitive to the correlation of the
p-values, especially at the tail of the distribution, lending to accurate approximations for small p-
values [82, 83]. This desirable property of this approximation (equation 2.3) with small p-values
is of particular interest in Hi-C data analysis. Liu et al. also argued that if the individual p-values
are conservative, pT will be conservative as well and the type I error is controlled.
2.2.2 HiC-ACT Test Statistic
Using the framework above, we specify the HiC-ACT statistic as follows. Let pij represent
the p-value for chromatin interaction between bin i and bin j from a specific Hi-C peak calling
method. Consider the null hypothesis that the contact frequency between bin pair (i,j) is due to




wmn tantp0.5´ pmnqπu (2.4)
Here, h is the local smoothing bandwidth. We followed the strategy adopted by the HiCRep [142]
method to determine the size of the smoothing window based on data resolution (Table A.1). We
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The criterion in equation 2.4 that determines which bin pairs are included in the chromatin
interaction neighborhood is derived from the equation of a diamond and ensures that the p-
values of all bin pairs pm,nq within a specified distance (h) from the bin pair of interest pi, jq
are combined. Note that the p-value for the bin pair itself contributes to the statistic, and thus the
smoothed p-value.
On the basis of the theory established, TACTij approximately follows a standard Cauchy





We can interpret p˚ij as the local neighborhood smoothed p-value. Intuitively, for a biologi-
cally meaningful chromatin interaction, all bin pairs in its neighborhood are more likely to have
significant p-values. Thus, the combined p-value p˚ij tends to be more significant and is driven by
small p-values in its neighborhood.
In an application to rare variant association analysis, Liu et al. demonstrated that the aggre-
gated Cauchy test is powerful under sparse alternatives [83]. Our application to Hi-C data is also
subject to sparse alternatives, since there are relatively few interactions due to chromatin looping
compared to the vast number of random events of chromatin collision. As shown by Liu and Xie,
the aggregated Cauchy test handles arbitrary dependency structures without knowledge of the
correlation values [82]. Through this property, HiC-ACT specifically accounts for the inherent




To implement HiC-ACT, we first obtain results from a standard peak caller not considering
spatial dependency. HiC-ACT only requires bin pair identifiers and corresponding p-values. Next,
we set h based on the data resolution (see Table A.1 for suggestions). Then, we identify a set bin
pairs pi, jq of interest, e.g., by selecting if pij is less than a specified threshold. We recommend
that this threshold depends on the total number of mapped reads in the data (Table A.2). For
each pi, jq pair, HiC-ACT determines all possible pm,nq pairs that meet criterion in equation 2.4,
calculates the weights, then computes TACTij and its corresponding p-value p
˚
ij for each pi, jq pair
in the set of interest using equation 2.6.
In Figure 2.1, we present a motivating example for HiC-ACT using 10Kb GM12878 Hi-C
data acquired from the Rao et al. study consisting of „4.9 billion pairwise contacts [102]. Each
colored pixel on the heatmap represents the strength of the FitHiC2 interaction (p-value), rep-
resented on the -log10 scale. This specific chromatin interaction (i.e., bin pair) is centered at
50,625,000 bp and 50,975,000 bp on chromosome 22 (marked by a blue “x”) has one end over-
lapping with a super enhancer reported by the Roadmap Epigenomics Consortium [26]) and the
other end overlapping with the transcription start site (TSS) [42] of the highly expressed TRABD
gene (FPKM = 17) [110]. However, when the data is down-sampled to „1 billion raw reads (a
more realistic sequencing depth), this interaction is not classified as a peak by FitHiC2 (p = 8.62e-
04) (see Table A.2 for details on how peaks were determined) (Figure 2.1A). When HiC-ACT
is applied to these FitHiC2 calls, the resulting p-value is highly significant (p = 2.73e-19) as
expected given the biological evidence. Figure 2.1B displays the corresponding heatmap for
FitHiC2 interactions/p-values called on the full GM12878 data („4.9 billion reads). The FitHiC2
p-value here for the specified interaction is 3.50e-11. Comparing Figure 2.1A to Figure 2.1B,
we notice that information is lost in data with shallower sequencing depth. HiC-ACT is able
to recover some information lost in Hi-C data with shallower sequencing depths by leveraging










































A ~1 billion raw reads
FitHiC2 p-value: 8.62e-04; HiC-ACT p-value: 2.73e-19
~4.9 billion raw reads
FitHiC2 p-value: 3.50e-11
B
0 10 20 30 40
−log  p-value 10
Figure 2.1: Motivating Example for HiC-ACT. FitHiC2 was applied to the GM12878 10Kb
Hi-C data down-sampled to „1 billion raw reads (A) as well as to the full GM12878 data („4.9
billion raw reads) (B). Each colored pixel on the heatmap represents the strength of the FitHiC2
interaction (p-value), represented on the -log10 scale. Here, the chromatin interaction (i.e., bin
pair) of interest is centered at 50,625,000 bp and 50,975,000 bp on chromosome 22 (marked by
a blue “x”). This interaction has one end overlapping with an identified super enhancer from
the Roadmap Epigenomics Consortium (marked by black bar on the left side) and the other end
overlapping with the transcription start site (TSS) for the TRABD gene, indicating a possible
functional interaction. However, this interaction is not marked as significant by FitHiC2 in the
lower sequencing depth (p = 8.62e-04) (A). When HiC-ACT is applied to these FitHiC2 calls, the
resulting p-value is highly significant (p = 2.73e-19) as expected given the biological evidence.
By using information from neighboring loci, HiC-ACT is able to recover some information lost
in Hi-C data with shallower sequencing depths.
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We also note that there are other bin pairs in this illustrated neighborhood with significant
interactions. As mentioned previously, HiC-ACT and FitHiC2 call peaks, rather than summits.
Calling peaks ensures a higher coverage of capturing functional chromatin interactions, as op-
posed to calling summits which can be driven by a combination of stochasticity and proximity to
bona fide interactions. Though the highlighted bin pair in Figure 2.1 does not have the strongest
signal, it completely overlaps the enhancer region, as opposed to, for example, the bin pair di-
rectly below that only partially overlaps with the enhancer region.
2.3 Results
2.3.1 Real Data-Based Simulations
We first used real data-based simulations to assess the performance of HiC-ACT. The simula-
tions were based on the 10Kb GM12878 (human lymphoblastoid cell line) Hi-C data consisting
of „4.9 billion pairwise contacts [102]. FitHiC2 results generated from this high-depth data were
treated as the truth. Approximately 1.57 million significant chromatin interactions were iden-
tified based on the criterion that the observed contact count ą 15, the expected contact count
ą 5, the ratio of observed to expected ą 1.5, and the p-value ă 1.0e-12. The p-value threshold
was informed by a recent study of 10Kb bin resolution deeply sequenced Hi-C data from human
brain cortex, where high-confidence regulatory chromatin interactions were determined using p ă
2.31e-11 [55].
To simulate more realistic sequencing depths and reflect the sequencing depths of most stud-
ies, we down-sampled the GM12878 Hi-C data to 10-40% of the original depth corresponding
to „0.5-2.0 billion raw reads. We performed down-sampling by generating multinomially dis-
tributed random number vectors. The parameters for the multinomial distribution were specified
with the down-sampling ratio (i.e., 10-40%) and the contact counts for bin pairs in the full data.
For each of these down-sampled data, we ran FitHiC2 then applied HiC-ACT. Following Hi-
CRep [142], we chose the smoothing bandwidth (h) to be 20 since we analyzed the data at 10Kb
resolution.
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Table 2.1: HiC-ACT considerably improves sensitivity with affordable loss of precision. Sen-
sitivity, precision, and corresponding F1 score of calling true peaks at various GM12878 10Kb
sequencing depths (in approximate billions of raw reads) is reported. Peaks are defined using
the guidelines in Table A.2 peaks called by FitHiC2 in the full GM12878 data („4.9 billion raw
reads) are treated as working truth.
Sensitivity/Recall Precision F1 Score
Sequencing Depth
(billions) HiC-ACT FitHiC2 HiC-ACT FitHiC2 HiC-ACT FitHiC2
0.5 0.44 0.06 0.92 1.00 0.59 0.11
1.0 0.57 0.16 0.93 1.00 0.71 0.28
1.5 0.65 0.28 0.93 1.00 0.77 0.44
2.0 0.70 0.40 0.93 1.00 0.80 0.57
Significant pairwise interactions were defined using sequencing depth-specific threshold of
minimum observed contact count, minimum expected contact count, global significant p-value
threshold, and for HiC-ACT, initial p-value filtering. In each case, a minimum ratio between
observed count and expected count of 1.5 was required to determine a significant interaction.
Table A.2 provides recommendations for defining significant interactions (i.e., peaks) based on
this simulation using sequencing depth-specific initial p-value filtering.
Assuming that deeply sequenced data is more reliable than data with shallower sequenc-
ing depth, we use the FitHiC2 peak calls (i.e., defined significant interactions) from the full
GM12878 data as the working truth in our simulations. Accordingly, we counted the number
of interactions correctly classified as significant or insignificant by HiC-ACT and FitHiC2 in each
down-sampled data. HiC-ACT correctly identified 75-641% more significant interactions than
FitHiC2 and achieves comparable precision (Table 2.1, Table A.3).
While HiC-ACT tends to be driven by the most significant interactions in a neighborhood
(those pairs with extremely small p-values), it maintains large (i.e., non-significant) p-values for
truly insignificant interactions. To demonstrate this, we calculated the sensitivity/recall and preci-
sion for correct identification of significant interactions for each method. Sensitivity, also known
as the true positive rate, is the proportion of true peaks identified out of the total number of true
27
peaks. Precision, also known as the positive predictive value, is the proportion of true peaks iden-
tified out of the number of interactions called as peaks. We also report the F1 score, defined as
the harmonic mean of precision and recall, where a value of 1 indicates perfect precision and
recall. Table 2.1 displays a summary of these results at various sequencing depths (in billions
of raw reads). HiC-ACT considerably improves sensitivity with affordable loss of precision, as
demonstrated by greater F1 scores, in all sequencing depths, though the largest improvements
are seen when sequencing depth is low. We note that the pattern of these results holds when the
global significance threshold is adjusted (Table A.3).
In the Hi-C peak calling problem, the number of true positives (significant interactions/peaks)
and true negatives (insignificant interactions/background noise) is highly unbalanced. Due to the
large proportion of true negatives, comparing sensitivity versus specificity is not ideal. Precision
versus recall is a more appropriate performance metric in this scenario [93]. Accordingly, speci-
ficity is omitted from Table 2.1 since the values for both methods are nearly 1 due to the large
number of insignificant interactions. Specificity, along with peak classification counts can be
found in Table A.3.
We can further examine the relationship between true positives (i.e., correctly identifying
significant interactions/calling true peaks) and false positives (i.e., incorrectly identifying interac-
tions as significant/calling false peaks) through precision recall curves (PRCs). Ideally, we desire
a method that has both high precision (few false positives) and high recall (few false negatives),
which is represented by a PRC located in the top right region of the plot. Figure 2.2 shows the
precision recall curves for calling true peaks (as defined in Table A.2) in the GM12878 10Kb
data when the data is down-sampled to different depths. Each panel displays the PRC for peaks
called using FitHiC2 as well as HiC-ACT. The shapes indicate where a specific p-value thresh-
old for defining FitHiC2/HiC-ACT peaks lies on the curve. For example, with „0.5 billion raw
reads, FitHiC2 (grey curve) achieves a recall of approximately 0.06 and precision near 1 when

























































HiC−ACT (p < 0.10)
HiC−ACT (p < 1e−3)
HiC−ACT (p < 1e−6)
HiC−ACT (p < 1e−8)
HiC−ACT (p < p')
Figure 2.2: Precision-Recall Curves (PRCs) for calling true peaks. Results for the GM12878
10Kb data down-sampled to „0.5 billion raw reads (A), „1.0 billion raw reads (B), „1.5 billion
raw reads (C), and „2 billion raw reads (D) are shown with a global p-value of 1.0e-12 for defin-
ing true peaks (using the full „4.9 billion raw read data as truth). Each panel displays the PRC for
peaks called using FitHiC2 (grey) as well as HiC-ACT with various initial filters (p-value ă 0.10
(orange), p-value ă 1.0e-3 (blue), p-value ă 1.0e-6 (green), p-value ă 1.0e-8 (yellow), p-value
ă p1 (pink)). The pink dashed line indicates HiC-ACT applied with our suggested filter (values
of p1 can be found in Table A.2). Shapes indicate where a specific p-value threshold for defining
FitHiC2/HiC-ACT peaks lies on the curve.
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value filtering of 1.0e-3 (blue curve) is able to significantly improve peak classification, achieving
recall of approximately 0.36 with negligible loss in precision (0.97) (Figure 2.2A).
The pink dashed curves correspond to HiC-ACT applied with our suggested filter p1 (values
of p1 can be found in Table A.2). As detailed in Table A.2, we suggest using a more stringent
initial p-value filter for data with high sequencing depth and using a more lenient initial p-value
filter for data with shallow sequencing depth. As the sequencing depth increases, the choice of
initial p-value filter has less effect on the precision and recall of HiC-ACT (Figure 2.2D). In
general, HiC-ACT peak calling can be made more conservative (or liberal) by choosing a more
stringent (or lenient) initial p-value filtering threshold. In other words, HiC-ACT allows us to
improve precision at the cost of recall (e.g., detection of true peaks), by select a smaller initial
p-value filter. We obtained similar results when the global significance threshold is adjusted
(Figures A.1-A.2, Table A.3).
Lastly, the precision-recall curves also suggest that type-I errors are largely maintained in
that the curves (particularly the parts where the significant thresholds were selected) are rather
flat, reflecting no big drop in precision. Given the much larger number of non-peaks compared to
peaks, a small increase in type-I error could lead to a rather drastic increase in the denominator
for precision calculation, which would incur a big drop in precision. Therefore, it is reassuring to
observe that the HiC-ACT precision-recall curves remain largely flat.
HiC-ACT also shows improved power to detect significant interactions with low normalized
contact frequency. Specifically, we compared the observed to expected contact count ratios be-
tween methods for their most significant interactions (ranked p-values). Figure 2.3 shows the
distribution of the ratios of the most significant true peaks (significant interactions called in the
full data) called by each method in the „1 billion raw read data. The median ratio for HiC-ACT
is „3.3 (0.5 on the log10 scale) across all top n peaks, whereas the median ratio for FitHiC2 de-
creases from 6 to 4.5 (0.8 to 0.7 on the log10 scale) as the number of top peaks increases. The ob-
served to expected contact count ratios of HiC-ACT are significantly lower than those of FitHiC2
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Figure 2.3: HiC-ACT demonstrates improved power to detect peaks with low normalized counts.
Violin plot showing the distribution of the log10 ratio of observed contact counts to expected
contact counts for the top true peaks called by HiC-ACT and by FitHiC2 in the GM12878 10Kb
data down-sampled to 1 billion raw reads. Significant interactions were defined using the cri-
teria specified in Table A.2, and the true peaks used here further require that the interaction be
identified as significant in the full data. Each violin displays the median ˘ 1 standard deviation.
(Wilcoxon test p-value ă 2.2e-16) in each case. We reached similar conclusions at other sequenc-
ing depths (0.5-2 billion raw reads, data not shown).
2.3.2 HiC-ACT Identifies Biologically Relevant Interactions
2.3.2.1 GM12878 Roadmap Epigenomics Consortium Enhancers
Using the same GM12878 Hi-C data at 10Kb bin resolution, we compared the peaks called
by HiC-ACT and FitHiC2 to typical enhancers (TEs) and super enhancers (SEs) from the Roadmap
Epigenomics Consortium [26]. There are 10,335 enhancers in total, 252 of which are super-
enhancers. First, we identified which peaks have one end overlapping with an enhancer and the
other end overlapping with the TSS [42] of an expressed gene [110] (FPKM ą 1), and defined
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Figure 2.4: Comparing HiC-ACT and FitHiC2 peak calls with Roadmap Epigenomics Consor-
tium enhancers in GM12878 10Kb Hi-C data. The total number of super-enhancer-promoter
(SE-P) interactions (A) or typical enhancer-promoter (TE-P) interactions (B) identified by each
method at various sequencing depths (in „billions of raw reads). continued
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Figure 2.4: (continued) The total number of unique super-enhancers (SEs) (C) or unique typical
enhancers (TEs) (D) captured is also reported along with the odds ratios and corresponding
p-values for number of enhancers identified (out of 252 total SEs and 10,335 total TEs). (E).
The number of HiC-ACT-specific, FitHiC2-specific, and shared interactions overlapping a SE-
promoter interaction within a specified number of top peaks (ranked p-values) in the GM12878
data down-sampled to „1 billion raw reads, demonstrating that the most significant interactions
identified by each method are different. The breakdown of overlap counts for this example is
detailed for the top 100,000 (F) and the top 200,000 peaks (G).
At each sequencing depth, we count the total number of super-enhancer-promoter (SE-P)
interactions (Figure 2.4A) and typical enhancer-promoter (TE-P) interactions (Figure 2.4B) iden-
tified by each method. HiC-ACT interactions overlap more with SE-P and TE-P interactions
compared to FitHiC2 interactions. We also counted the total number of unique SEs (Figure 2.4C)
and unique TEs (Figure 2.4D) identified by each method. HiC-ACT is able to capture 90-95% of
the SEs and 63-81% of TEs, compared to 74-94% and 32-72%, respectively, captured by FitHiC2.
HiC-ACT appears to be less sensitive to sequencing depth than FitHiC2, and shows more signif-
icant improvements over FitHiC2 at shallower sequencing depths. Figure 2.4C-D displays the
total counts as well as the odds ratios and corresponding p-values for the number of enhancers
identified (out of 252 total SEs and 10,335 total TEs).
Next, we examined the total number of interactions overlapping an E-P interaction within a
specified number of top peaks (ranked p-values). At all sequencing depths („0.5-2.0 billion raw
reads), we observed improved performance of HiC-ACT over FitHiC2 for SE-promoter interac-
tions, and comparable performance between HiC-ACT and FitHiC2 for TE-promoter interactions
(Figure A.3). Moreover, the most significant interactions identified by each method are different
(Figure 2.4E-G). Figure 2.4E illustrates the number of HiC-ACT-specific, FitHiC2-specific, and
shared peaks that overlap a SE-promoter interaction at various top peaks. For example, out of
the top 100,000 peaks called by HiC-ACT and FitHiC2, 1,219 and 1,064 peaks overlap with SE-
promoter interactions, respectively. Among them, 688 peaks are HiC-ACT-specific, 513 peaks are
FitHiC2-specific, and 552 peaks are shared by two methods (Figure 2.4F). A similar example for
the top 200,000 peaks called by each method is displayed in Figure 2.4G.
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2.3.2.2 mESC ChIP-seq/ATAC-seq Peaks
We applied HiC-ACT (h=20) to FitHiC2 calls from Hi-C data from mouse embryonic stem
cell line (mESC) at 10Kb bin resolution [9]. Since this data is deeply sequenced („7 billion
reads), we chose a HiC-ACT initial p-value filter of 1e-6. This choice was informed by the
precision-recall curves in Figure 2.2D. Significant interactions were defined using the same
thresholds as the GM12878 data (observed contact count ą 15, expected contact count ą 5, the
ratio of observed to expected contact counts ą 1.5, and global p-value ă 1.0e-12). By these cri-
teria, HiC-ACT identifies „1.8 million significant interactions and FitHiC2 identifies „1 million
significant interactions.
We compared these peak calls to mESC ChIP-seq (H3K4me3, H3K4me1, H3K27ac, CTCF)
peaks [29, 21, 66] and ATAC-seq peaks [66]. We defined an overlap as a HiC-ACT/FitHiC2
called peak with either 10Kb bin overlapping a ChIP-seq/ATAC-seq peak. Further, we defined
a 10Kb bin as an enhancer bin or a promoter bin if it overlaps with a H3K27ac ChIP-seq peak
or H3K4me3 ChIP-seq peak and TSS [42] of an expressed gene [77] (FPKM ą 1), respectively.
We defined a HiC-ACT or FitHiC2 identified peak as an E-P interaction if one anchor bin is an
enhancer bin and the other anchor bin is a promoter bin. We similarly defined enhancer-enhancer
(E-E) and promoter-promoter (P-P) interactions.
Since HiC-ACT identifies more significant interactions than FitHiC2, we examined the same
number of top most significant interactions (ranked by p-values) called by each method for a fair
comparison. The most significant HiC-ACT-specific interactions show higher overlap with E-P,
E-E, and P-P interactions than the same number of most significant FitHiC2-specific interactions
(Figure 2.5A). The odds of the most significant HiC-ACT peaks showing overlap with E-P, E-E,
or P-P interactions is significantly higher (odds ratio estimate « 1.5, p-value ă 2.2e-16) than
the odds of the most significant FitHiC2 peaks (Table A.4). We observed similar results when
only considering the 1D overlaps in H3K27ac, H3K4me1, and H3K4me3 ChIP-seq peaks, and a
comparable performance between HiC-ACT and FitHiC2 in ATAC-seq peaks and CTCF ChIP-
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Figure 2.5: Comparing HiC-ACT and FitHiC2 peak calls with ChIP-seq and ATAC-seq peaks in
mESC data. (A) The number of most significant HiC-ACT and FitHiC2 interactions overlapping
with an enhancer mark or promoter mark. The most significant HiC-ACT-specific interactions
show higher overlap with enhancer-promoter, enhancer-enhancer, and promoter-promoter inter-
actions than the same number of most significant FitHiC2-specific interactions. (B) The number
of 1D overlaps between a 10Kb bin from most significant HiC-ACT and FitHiC2 interactions
and a ChIP-seq/ATAC-seq peak. We see similar results when only considering the 1D overlaps in
H3K27ac, H3K4me1, and H3K4me3 ChIP-seq peaks, and a comparable performance between
HiC-ACT and FitHiC2 in ATAC-seq peaks and CTCF ChIP-seq peaks. See Table A.4 for details
relevant to this figure.
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seq peaks (Figure 2.5B). Table A.4 lists the number of overlaps displayed by Figure 2.5 at various
numbers of top peaks.
2.3.2.3 mESC FANTOM5 and dbSUPER Enhancers
Next, we compared the mESC HiC-ACT and FitHiC2 calls at 10Kb resolution to mESC
enhancers cataloged in the FANTOM5 database [22, 1] and from the dbSUPER database [63].
FANTOM5 includes 43,662 enhancers and dbSUPER includes 229 super enhancers. For each
set of enhancers, we counted how many interactions called by HiC-ACT and FitHiC2 overlap
with an enhancer-promoter (E-P) interaction (one end overlapping with an enhancer and the other
end overlapping with the TSS [42] of an expressed gene [77]). The most significant HiC-ACT
peaks have approximately 1.4-2 times the odds of overlapping an E-P interaction than the same
number of most significant FitHiC2 peaks. Figure 2.6A displays the number of peaks overlapping
E-P interactions for each enhancer database and method, as well as the corresponding odds ratio
estimates and p-values.
We next examined the total number of unique enhancer-promoter interactions identified
by each method for the enhancers in the dbSUPER and FANTOM5 databases (Figure 2.6B).
HiC-ACT identifies 218 more dbSUPER super-enhancer-promoter interactions and 29,632 more
FANTOM5 enhancer-promoter interactions than FitHiC2. Further, one enhancer may interact
with multiple promoters, so we also report the total number of unique enhancers among the iden-
tified E-P interactions. Interestingly, all FitHiC2 identified dbSUPER enhancers and all but 14
FitHiC2 identified FANTOM5 enhancers are also identified by HiC-ACT.
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Figure 2.6: Comparing HiC-ACT and FitHiC2 peak calls with dbSUPER super enhancers and
FANTOM5 enhancers in mESC data. (A) The number of interactions called by HiC-ACT and
FitHiC2 that overlap with an enhancer-promoter (E-P) interaction (one end overlapping with an
enhancer and the other end overlapping with the TSS of an expressed gene). More HiC-ACT
peaks overlap with an enhancer than FitHiC2 peaks among their respective most significant
100,000, 250,000, and 500,000 interactions. Odds ratios are reported along with their statistical
significance (p-value). (B) The total number of E-P interactions identified by each method for the
enhancers in the dbSUPER and FANTOM5 databases. Sine some enhancers may interact with
multiple promoters, the total number of unique enhancers among the identified E-P interactions is
also reported. The dashed grey line indicates the total number of enhancers in the database.
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2.4 Discussion
Hi-C has been widely adopted to study chromatin spatial organization with several peak
callers proposed and commonly used to analyze and interpret this data. Here we present HiC-
ACT, a method to improve the detection of chromatin interactions by post-processing 3D peak
calling results from methods relying on the assumption that pairs of chromatin interactions are
statistically independent. HiC-ACT leverages the power of an aggregated Cauchy test to specifi-
cally account for the correlation without requiring any information about its structure. We demon-
strated that HiC-ACT can improve sensitivity, while maintaining comparable precision. We also
provide guidelines regarding decision rules to maintain a desired type I error.
As expected, we observed most pronounced improvement over FitHiC2 when sequencing
depth is less than one billion reads, which is the typical depth for the vast majority of Hi-C
datasets generated to date. As shown through our analyses of the GM12878 data, the perfor-
mance of FitHiC2 decreases as sequencing depth decreases; therefore, there is relatively more
room for improvement for Hi-C data with lower sequencing depth. Further, Hi-C data with shal-
lower sequencing depths are more likely than Hi-C data with higher sequencing depths to have
lower signal to noise ratios for some significant interactions, and by borrowing information from
neighboring interactions, HiC-ACT is able to more powerfully identify these interactions than
FitHiC2. Even with increasing sequencing depth anticipated in some future Hi-C studies, we
consider HiC-ACT useful as it will allow more powerful 3D peak calling at finer resolution (e.g.,
5Kb or even 1Kb resolution, particularly when cut with the appropriate restriction enzymes such
as the 4 base pair cutter MboI or DpnII).
It is unsurprising that the most significant interactions called by each method are different.
Intuitively, all bin pairs in the neighborhood of a biologically relevant interaction are more likely
to be significant than randomly colliding bin pairs. However, in Hi-C data with shallower se-
quencing depths, the signal strengths for all bin pairs in the neighborhood may not be adequately
reflected in the unsmoothed p-values. We have demonstrated that HiC-ACT has higher power to
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detect peaks with lower signal to noise ratio than FitHiC2 (Figure 2.3). Accordingly, for highly
significant interactions, HiC-ACT is more likely than FitHiC2 to call peaks in its neighborhood as
well, lending to the differences observed in the top peak calls of each method.
We note that while FastHiC accounts for spatial dependency, it is not intended to be used as
a chromosome-wide peak caller in high resolution Hi-C data, like FitHiC2. We find that FastHiC
underperforms both HiC-ACT and FitHiC2 in this scenario (Figure A.4). Although HiC-ACT
can theoretically be applied to HiCCUPS results, we consider such application inappropriate due
to the intrinsic nature of HiCCUPS to call summits in peak regions. HiCCUPS contrasts each
chromatin loci pair with its local neighborhood; however, our goal is to call peaks by borrowing
information from the neighborhood.
HiC-ACT is computationally efficient and scalable. HiC-ACT can process 25,000 pairwise
interactions in „6 minutes with „2GB memory and 0.5 million pairwise interactions in „2 hours
with „30GB memory, using a 2.50 and 3.40 GHz Intel processor, respectively. Note that chro-
mosome 1 has „90,000 and „168,000 pairwise interactions, at 10Kb resolution, passing the sug-
gested initial p-value filter in the „0.5 and „1 billion raw reads GM12878 Hi-C data, respectively.
Future work may involve fine tuning the smoothing parameter, particularly for 1Kb bin res-
olution Hi-C data, which will be necessary as high resolution Hi-C data becomes more widely
available, and investigating different weight functions. In addition, it would be interesting to in-
vestigate applying a summit caller to the HiC-ACT adjusted results, which may help to identify
the most important interactions.
By identifying statistically significant long-range interactions with enhanced statistical power
and improved computationally efficiency, HiC-ACT can improve our knowledge regarding re-
gions with regulatory potential, and aid to establish links between cis-regulatory regions and their
target genes. We anticipate HiC-ACT will become a convenient tool for many researchers.
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CHAPTER 3: SUPER-INTERACTIVE PROMOTERS PROVIDE INSIGHT INTO CELL
TYPE-SPECIFIC REGULATORY NETWORKS IN BLOOD LINEAGE CELL TYPES
3.1 Introduction
As previously discussed in Section 1.3, chromatin spatial organization plays a critical role in
genome functions such as gene expression regulation. Existing studies of chromatin conforma-
tion have primarily focused on potential enhancers interacting with gene promoters. By contrast,
the interactivity of promoters per se, while equally critical to understanding transcriptional con-
trol, has been largely unexplored, particularly in a cell type-specific manner for blood lineage cell
types. As described in Section 1.4.4, Promoter Capture Hi-C (pcHi-C) is specifically enriched
for promoter sequences and enables the genome-wide detection of distal promoter-interacting re-
gions (PIRs). Recent studies have demonstrated that pcHi-C analysis can be leveraged to provide
insight into gene expression control and the function of non-coding disease-associated sequence
variants [114].
In this chapter, we focus on characterizing promoter-centric chromatin spatial interaction pro-
files, across a compendium of cell types in the hematopoietic lineage. Due to the relative ease of
measuring blood cells, rich genomics data is available for hematopoietic cells. Further, different
hematopoietic cell types play different roles in blood cell generation and function and correspond
to different phenotypic traits (for example inflammation, autoimmunity, and infection phenotypes
for white blood cell types, thrombosis and hemostasis related phenotypes for platelet producing
megakaryocytes), emphasizing the importance of studying them in cell type-specific manner [80].
Blood cells are highly relevant tissues for many complex phenotypes, including infectious disease
susceptibility (including COVID-19), disease related biomarkers such as telomere length or cir-
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culating inflammatory cytokines, thrombosis (including venous thromboembolism and stroke),
asthma and other respiratory diseases, and autoimmune conditions [2]. Understanding of inter-
actions of gene promoters and their regulatory regions in specific blood cell types, as opposed to
simple analysis of “whole blood”, can lead to improved annotation of genome-wide association
study (GWAS) identified loci and their target genes, and thus of the genetic mechanisms underly-
ing complex disease risk. Hematopoietic SIPs are thus of broad interest for understanding gene
regulation and its connection to disease risk in human populations.
In this study, we identify and characterize SIPs in human blood cells using pcHi-C data from
the Javierre et al. study [65]. We find that SIPs tend to be cell type-specific or shared across
all cell types. Through examining the differences between SIPs and non-SIPs in terms of their
interaction profiles as well as their genes, we find that SIPs share common properties across cell
types. Importantly, we demonstrate how studying SIP networks may provide insight into the
complex regulation of promoters as well as potential functional interactions.
3.2 Results
3.2.1 Chromatin Interactivity of Cell Type-Specifically Expressed Genes
We first explored the relationship between chromatin interactivity and gene expression in
a cell type-specific manner. We examined this relationship using pcHi-C data from Javierre et
al. [65] and gene expression data from BLUEPRINT [18], in each of the five hematopoietic cell
types: erythrocyte (Ery), macrophage/monocyte (MacMon), megakaryocyte (MK), naive CD4
T-cell (nCD4), and neutrophil (Neu) (Methods). We classified genes as “specific” (expressed in
a cell type-specific manner) or “shared” across the five cell types (Methods). The promoters for
cell type-specific genes have significantly more interactions than the shared genes across all five
cell types (p-value ă 0.05) (Figure B.1a-e), indicating that cell-type specifically expressed genes
exhibit higher levels of chromatin interactivity in the corresponding cell type than shared genes.
Similar results were observed by Song et al. in neuron cells [120].
41
3.2.2 Inequality in the Promoter Interactome: Few Super-Interactive Promoters
For each cell type, we ranked the promoter-containing anchor bins (baits) according to their
cumulative interaction scores (Methods) (Figure 3.1). We find that a small number of promoter
baits („7.5%) have extremely high cumulative interaction scores, as defined based on the curve
inflection point in each cell type, and annotated them as super-interactive promoters (SIPs). In
total, we annotate 1,157, 808, 1,287, 993, and 861 SIPs in erythrocytes, macrophages/mono-
cytes, megakaryocytes, naive nCD4 T-cells, and neutrophils, respectively (Table B.1). These
SIPs can be cell type-specific or shared across cell types. There are 170 SIPs shared across all
five cell types, as well as 189, 107, 302, 283, and 274 cell type-specific SIPs in erythrocytes,
macrophages/monocytes, megakaryocytes, naive nCD4 T-cells, and neutrophils, respectively.
Figure B.2 details how the SIPs are shared across the different cell types (Supplemental File 1).
Similar to GTEx analyses of eQTLs’ tissue specificity [23, 24], the most common configurations
pertain to cell type-specific SIPs and shared SIPs (across all five cell types). In addition, principal
component analysis (PCA) on the cumulative interaction scores reflects expected correlations be-
tween cell type-specific SIPs in each cell type, as well as between any SIP and those SIPs shared
by all five cell types (Figure B.3).
Moreover, many cell type-specific SIPs correspond to known lineage-specific genes and have
PIRs overlapping relevant GWAS variants (examples annotated by red dots in Figure 1a-e) (Meth-
ods, Supplemental File 2). For example, the neutrophil SIP gene DOCK8 is an immunodeficiency
gene that is expressed in resting human neutrophils [85], and the macrophage SIP gene FMNL2 is
most highly expressed in macrophages and is cell type relevant enrichment [125, 72]. The naive
CD4 T-cell SIP gene CD6 is a strong positive control, as this gene is essentially only expressed
in CD4 T-cells [30]; BACH2 plays a vital role in maintaining naive CD4 T-cells and regulating
immune homeostasis [71]. All of these SIPs genes have at least one PIR overlapping a GWAS
identified SNP.
The unusually high cumulative interaction scores at SIPs are driven by a large number of
interactions, rather than a few interactions with large scores (Figure 3.2a-b). SIP baits have a
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Figure 3.1: There are few super-interactive promoters (SIPs) in the chromatin interactome.(a)-
(e) Hockey plots for each cell type show the ranked cumulative interaction scores for pcHi-C
promoter-containing anchor bins (baits). Promoters to the right of the blue vertical line are
classified as super interactive promoters (SIPs), as they exhibit unusually high levels of chro-
matin interactivity. Red dots highlight the highest ranked cell type-specific SIP genes with a PIR
overlapping a relevant GWAS identified SNP.(f) Total number of SIPs annotated per cell type.
significantly greater number of other end interactions (i.e., PIRs) compared to non-SIP baits in
each cell type (Wilcoxon p-value ă 2.2e-16). The median number of significant interactions
is 38-61 for SIPs and only 4-7 for non-SIPs. SIPs interact with 9 times more PIRs than non-
SIPs on average. However, the median CHiCAGO score [15] of significant interactions per bait,
although statistically different, is comparable between SIPs and non-SIPs (the median is „8.4 for
SIPs and „6.4 for non-SIPs).
3.2.3 SIPs and Super Promoter-Interacting Regulatory Regions
In each cell type, „59% of PIRs interact with a single promoter fragment while only „10%
of PIRs interact with 4 or more promoter fragments. Therefore, we define a super promoter-
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Figure 3.2: SIPs are driven by a large number of interactions. (a) Distribution of the number of
significant interactions (log10 scale) between promoter bait and promoter interacting regions
(PIRs) for SIPs and non-SIPs in each cell type. (b) Distribution of the median CHiCAGO score
(log10 scale) of significant interactions per promoter bait for SIPs and non-SIPs in each cell
type. The width of each violin corresponds to the frequency of interaction count (a) or median
CHiCAGO score (b). The median of each distribution is marked by a black dot. (c) The pro-
portion of SIP and non-SIP baits with super PIRs in each cell type. SIPs interact with a larger
proportion of super PIRs than non-SIPs in each cell type (the red asterisk (˚) denotes Chi-square
p-value ă 3.2e-35). (d) Distribution of PIR scores for SIPs and non-SIPs in each cell type. SIPs
have significantly higher PIR scores than non-SIPs in each cell type (the red asterisk (˚) denotes
Wilcoxon p-value ă 1.7e-50). Details for panels (c) and (d) can be found in Table B.1.
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interacting region (super PIR) as a PIR interacting with at least 4 promoter fragments. As ex-
pected, SIPs interact with a larger proportion of super PIRs than non-SIPs in each cell type (Chi-
square p-value ă 3.2e-35) (Figure 3.2c, Table B.2). Approximately 74-90% of SIPs interact with
a super PIR, whereas only 49-67% of non-SIPs interact with a super PIR. We assign each pro-
moter region (bait) a PIR score, defined by its PIR with the maximum number of interactions.
SIPs have significantly higher PIR scores than non-SIPs in each cell type (Wilcoxon p-value ă
1.7e-50) (Figure 3.2d, Table B.3). The median PIR score is „6 for SIPs and „4 for non-SIPs. The
basic characteristics of SIPs (e.g., number of PIRs and proportion with super PIRs) are consistent
across all five hematopoietic cell types.
3.2.4 SIP PIRs Overlap with ATAC-seq Peaks and Relevant GWAS Variants
We can further characterize SIPs through their PIRs by looking at the proximity of PIRs to
open chromatin regions and known GWAS variants. In each cell type, over 96% of SIPs have a
PIR overlapping an ATAC-seq peak of the corresponding cell type [126], compared to 63-83% of
non-SIPs. In each cell type, the proportion of SIPs with a PIR that overlaps a cell type-specific
ATAC-seq peak is significantly greater than the proportion of non-SIPs with a PIR that overlaps
an ATAC-seq peak (Chi-square p-value ă 2.9e-45) (Figure 3.3a). We then compared the number
of PIRs overlapping cell type-specific ATAC-seq peaks, for SIPs and non-SIPs (Figure 3.3b). In
each cell type, significantly more SIP PIRs overlap with cell type-specific ATAC-seq peaks com-
pared to non-SIP PIRs (t-test p-value ă 1.2e-162). The median number of ATAC-seq overlaps
per bait is 8-22 for SIPs and only 1-3 for non-SIPs. Details on the number of overlaps as well as
specific p-values are reported in Table B.3. Note that neutrophils are excluded from this analysis
due to data availability (Supplemental Note 1).
Next, we examine the overlap between GWAS variants and PIRs. In each cell type, SIPs have
significantly greater odds (3-4 times the odds) of having at least one PIR overlap with a relevant
blood cell trait associated variant, compared to non-SIPs (Methods) (Figure 3.3c). We found
similar results when considering only cell type-specific SIPs (Figure B.4) and observed that the
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basic characteristics of SIPs are consistent across all five cell types. Details regarding SIP PIRs
and their overlaps with relevant variants can be found in Supplemental File 2.
Figure 3.3: SIP PIRs overlap with ATAC-seq peaks and relevant GWAS variants. (a) In each
cell type, the proportion of SIPs with a PIR that overlaps a cell type-specific ATAC-seq peak is
significantly greater than the proportion of non-SIPs with a PIR that overlaps an ATAC-seq peak
(the red asterisk (˚) denotes Chi-square p-value ă 2.2e-16). (b) The distribution of the number
of PIRs (other ends) overlapping with ATAC-seq peaks for each pcHi-C bait (y-axis) for each
cell type (x-axis). In each cell type, significantly more SIP interactions overlap with ATAC-seq
peaks compared to non-SIP interactions (the red asterisk (˚) denotes two-sided t-test p-value ă
1.2e-162). (c) In each cell type, SIPs have 3-4 times the odds of having at least one PIR overlap
with a relevant GWAS variant, compared to non-SIPs. Odds ratio estimates (purple dots) and
corresponding 95% confidence intervals are shown.
3.2.5 SIP Subnetworks
By incorporating GWAS and open chromatin data with the pcHi-C data, we can determine
SIP subnetworks that may provide insight into potential functional interactions. These SIP sub-
networks are defined as having at least two PIRs that each overlap with a relevant statistically
independent SNP and a cell type-specific ATAC-seq peak (Methods). We identify 2-15 SIP sub-
networks in each cell type/phenotype combination (Methods, Supplemental File 2). Details of the
interactions and SNPs involved in these SIP subnetworks can be found in Supplemental File 3.
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We highlight two examples of SIP subnetworks in Figure 3.4. Figure 3.4a depicts the megakary-
ocyte SIP with bait located at the EPHB3 gene interacting with three distinct regions that over-
lap with a total of 8 independent SNPs related to platelet count. These PIRs also overlap with
megakaryocyte ATAC-seq peaks, and are near the key platelet related gene THPO or throm-
bopoietin, variants in which can lead to thrombocythemia (OMIM 600044). Thrombopoietin is
essential for megakaryocyte proliferation and maturation, as well as for production of platelets.
EPHB3 encodes ephrin receptor B3, and plays roles in development, cell migration, and adhe-
sion; variants in family member EPHB2, which also binds ephrin-B family ligands, are associated
with a Mendelian bleeding disorder characterized by deficiencies in agonist-induced platelet ag-
gregation and granule secretion (OMIM 600997). This SIP network suggests that THPO locus
variants may also play a role in regulation of EPHB3.
Figure 3.4b depicts the naive CD4 T-cell SIP with bait located at the ETS1 gene interacting
with three distinct PIRs that each overlap with an independent GWAS SNP related to lymphocyte
count as well as a naive CD4 T-cell ATAC-seq peak. ETS1 is a transcription factor highly ex-
pressed in CD4 T-cells known to regulate differentiation, survival and proliferation of lymphoid
cells [18]; the ETS1 locus is an important genetic regulator of risk for the autoimmune disorder
systemic lupus erythematosus [53]. These SIP networks show the complex regulation of pro-
moters for important hematopoietic cell type genes, with multiple distinct genetic variants and
regions of open chromatin acting together to regulate genes.
3.2.6 SIPs Align with Gene Expression Levels in a Cell Type-Specific Manner
SIPs can also be characterized by their genes, and each SIP bait may correspond to more than
one gene. There are 1,514, 1,093, 1,752, 1,393, and 1,201, SIP genes in erythrocyte, macrophage/-
monocyte, megakaryocyte, naive CD4 T-cell, and neutrophil SIPs, respectively (Supplemental
File 1). Within each cell type, we ranked the genes according to their expression levels and cal-
culated the fold enrichment of the genes classified as SIPs for higher gene expression (detailed
in Methods). All five cell types have well-expected trends in the relationship between SIP enrich-
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Figure 3.4: SIP subnetworks show the complex regulation of promoters for important hematopoi-
etic cell type genes. First panel: position of SNPs. Second panel: position of SIP bait or PIR
target gene(s), where the color corresponds to their exponentiated BLUEPRINT gene expression
(equivalent to RKPM) in the respective cell type. Third panel: cell type-specific ATAC-seq peaks.
Fourth panel: CHiCAGO scores (blue) of the interactions (depicted by purple arcs) between
the SIP bait (dark grey) and the SIP PIRs (light grey). (a) Example of a megakaryocyte SIP
subnetwork for platelet count related variants. (b) Example of a naive CD4 T-cell SIP subnetwork
for lymphocyte count related variants.
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Figure 3.5: SIP genes tend to express at a higher level in the corresponding cell type. In each cell
type, SIP genes with the highest (1st) ranked expression show greater fold enrichment over the
lowest (5th) ranked gene expression. The size of the circle denotes the fold-change and the color
denotes the Chi-square significance of enrichment. The Cochran-Armitage trend test p-value
(one-sided) is also reported.
ment and gene expression (Figure 3.5). For example, in erythrocytes there is 1.9 fold enrichment
for a gene having a SIP in the highest quintile of gene expression (1st ranked) over the lowest
(5th ranked) gene expression quintile (Chi-square p-value = 8.7e-14).
3.2.7 Partitioned Heritability for Cell Type-Specific SIP PIRs
We leveraged linkage disequilibrium score regression [12, 40] (LDSC) using the cell type-
specific SIP PIRs to partition the SNP heritability using trans-ethnic GWAS summary statistics
of 15 blood cell traits [19] (Methods). Enrichment scores and corresponding p-values for each
cell type and blood cell trait are displayed in Figure B.7 and Figure 3.6. Erythrocyte-specific
SIPs are significantly enriched for red blood cell related traits including MCH, MCHC, MCV,
RBC and RDW. Further, megakaryocyte-specific SIPs are significantly enriched for PLT, naive
CD4 T-cell-specific SIPs are significantly enriched for LYM, and neutrophil-specific SIPs are
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significantly enriched for NEU and WBC. These results all show expected trait enrichments for
each cell type. We also notice some less expected enrichments between erythrocyte-specific
SIPs and NEU, as well as between neutrophil-specific SIP genes and MCH, for example. While
macrophage/monocyte-specific SIPs are not enriched for white blood cell related traits (including
monocyte counts), this may be due to the small number of macrophage/monocyte-specific SIPs
(107) relative to the larger number of naive CD4 T-cell- and neutrophil-specific SIPs (283 and
274, respectively). When considering the PIRs of all SIPs, rather than only cell type specific SIP
PIRs, macrophage/monocyte SIPs are significantly enriched for MONO and WBC (Figure B.8).
Figure 3.6: Partitioned SNP heritability for blood cell traits shows enrichment between cell
type-specific SIPs and relevant traits. Enrichment score p-values (-log10 scale) for cell type-
specific genes and 15 blood cell traits. Bars passing the inner ring (1.3) correspond to statistically
significant enrichment scores (p-value ă 0.05). See Figure B.7 for enrichment scores.
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3.2.8 Cell Type-Specific SIP Genes
We defined cell type-specific SIP genes as genes corresponding to cell type-specific SIP
baits that are not captured by any other promoter baits (some genes may be captured by multi-
ple pcHi-C baits). In total, we annotate 251, 125, 385, 386, and 384 cell type-specific genes in
erythrocytes, macrophages/monocytes, megakaryocytes, naive CD4 T-cells, and neutrophils, re-
spectively (Table B.1). We also annotate 234 “shared” SIP genes (corresponding to SIPs shared
across all five cell types). Note that a SIP may be a promoter for multiple genes, and thus the
number of cell type-specific SIP genes may be greater than the number of cell type-specific SIPs.
Full details of the SIP genes in each cell type can be found in Supplemental File 1.
We notice some trends in the gene expression of the 234 shared SIP genes that suggests
that they have elevated expression levels in hematopoietic cell types [18] compared to the gene
expression in various other tissues (Methods, Figure B.5). We find similar trends when compar-
ing the gene expression of cell type-specific SIP genes to the expression in various other tissues
(Figure B.6).
3.3 Discussion
Hi-C has been widely adopted to study chromatin spatial organization. pcHi-C, a derivative
of the Hi-C technology, enables the study of the promoter interactome, specifically. Importantly,
recent studies have demonstrated the ability of pcHi-C analysis to link non-coding variants to
their target genes.
By analyzing pcHi-C data, we catalogue super-interactive promoters (SIPs) in five blood cell
types and present characteristics and analysis of SIPs in blood cell lineages. The characteristics
of SIPs identified in blood cell lineages are consistent with those described of SIPs identified
in the brain cortex [120], including enrichment for key blood lineage-specific genes, cell type
specificity for most identified SIPs, and cell type-specific SIP enrichment in cells with higher
expression of the regulated genes. We also demonstrate that SIPs share common properties across
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cell types, but align with cell type-specific genes. In our analyses, we find that SIPs’ regulatory
networks are more likely to overlap with relevant GWAS variants and ATAC-seq peaks than
non-SIP regulatory networks. We further find that cell type-specific SIP genes show enriched
heritability in blood cell trait GWAS summary statistics. In conjunction with other functional
genomic data, we hypothesize that SIPs in relevant hematopoietic cell types can help identify
GWAS variant target genes.
Now that many blood cell lineage SIPs have been identified, a logical next step would be
to disrupt SIPs or SIP PIRs and evaluate the effects on hematopoiesis. SIPs driven by few super
strong interactions vs many significant (not necessarily all strong) interactions will have different
implications for the design and prioritization of functional experiments. In our study, the latter
seems to be the norm. Most SIPs are linked to multiple regulatory regions (as opposed to just
having a few very strong interactions). These multiple regulatory regions are likely key for or-
chestrating fine transcriptional control of genes with SIPs. Multiple regulatory regions may also
provide a level of “redundancy”, ensuring that even in the presence of an enhancer-disrupting
genetic variant, appropriate transcriptional regulation can occur for important genes in a given
hematopoietic cell type. Many key GWAS loci show allelic heterogeneity, with multiple rare and
common variants (both coding and noncoding) impacting gene regulation (for example, at the
MPL or JAK2 locus for platelet traits [19, 37, 130]. Particularly for SIPs, genetic or epigenetic
perturbations of one of these many putative regulatory regions (some of which may be tagged
by statistically distinct GWAS SNPs) may be compensated for by other regulatory regions in the
orchestra, leading to no apparent effect in vitro even when the perturbed region is functional in its
native context. Researchers should consider this limitation when prioritizing loci and interpreting
functional validation experimental results and may want to consider approaches that genetically
or epigenetically edit multiple variants or regulatory regions simultaneously [103]. Cell type
specificity of SIPs and their PIRs should also be considered in linking GWAS variants to genes
and in design of functional experiments.
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The success of SIP characterization in neuronal, and now hematopoietic lineages, suggests
the value of cataloguing SIPs in other cell types and incorporating those SIPs with results of
GWAS analysis for relevant traits. It would also be interesting to examine condition-specific SIPs,
such as different molecular environments triggered by drugs, toxic chemicals, diet, or stress, in
various cell types. Doing so would allow for investigation on how gene expression varies in a
cell-type specific manner under different environmental conditions. In addition, future work may
involve exploring the relationship between super PIRs and super enhancers. Further experimental
work to validate the cell type-specific SIP genes and the connection of these genes to correspond-
ing blood cell traits will be required, but many attractive candidates have been identified through
our systematic evaluation of promoters and their interacting regulatory regions in hematopoietic
cell types.
3.4 Conclusions
We identified 808-1287 SIPs from major blood cell types, corresponding to 1,093-1,752 SIP
genes, among which 125-386 are cell type specific. These SIPs and SIP genes in blood cells will
be valuable not only for studying hematological traits but for many complex phenotypes. SIPs
manifest significant differences from non-SIPs in at least four aspects: (1) promoter-interacting
regions (PIRs) of SIPs are more likely to overlap with cell type-specific open chromatin regions;
(2) SIP PIRs, compared to PIRs for non-SIPs, are enriched with GWAS variants associated with
relevant hematological traits; (3) SIP genes tend to express at a higher level in the corresponding
cell type; (4) SIP genes show enriched heritability of relevant blood cell traits.
We provide mechanistic hypotheses regarding the formation of SIPs. To be identified as a
SIP, a promoter can be driven by few super strong interactions or many significant (not necessar-
ily all strong) interactions. Importantly, we find that the latter seems to be the norm. This finding
sheds light regarding the formation of SIPs: to ensure the expression level of some critical gene
(here a SIP gene), multiple regulatory regions are likely key for orchestrating fine transcriptional
control. These multiple regulatory regions provide a level of “redundancy”, ensuring that even
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in the presence of genetic variant(s) that disrupt some enhancer(s), appropriate transcriptional
regulation can still be maintained in a given hematopoietic cell type. This finding also has im-
portant implications for the interpretation and functional follow-up of hundreds of thousands of
GWAS findings. These multiple regulatory regions for one SIP gene help explain multiple inde-
pendent GWAS signals at one locus. We provide concrete examples, including the EPHB3 locus
associated with platelet count, where we present three distinct regulatory regions overlapping
a total of 8 independent SNPs. In addition, due to the potential redundancy, functional experi-
ments may also need to consider disrupting multiple regulatory regions simultaneously rather
than individually to observe palpable effects. In summary, we believe our work presents impor-
tant findings governing the orchestrated transcriptional control in blood lineage cell types, and
provides valuable insights and resources for the interpretation and follow-up of GWAS findings
of many complex traits.
3.5 Methods
3.5.1 Cell Type Groups
There are eight hematopoietic cell types in the pcHi-C data [65]: M0 macrophage, M1
macrophage, M2 macrophage, monocyte, neutrophil, erythrocyte, naive CD4 T-cell, and megakary-
ocyte. Since monocytes circulate in the blood and exist in tissues as macrophages in their mature
form, we grouped the monocytes with the three macrophage types (by taking the average of the
gene expression in BLUEPRINT [18] and the CHiCAGO [15] scores in pcHi-C data) to form one
group. Thus, we focus on five cell types throughout this study.
3.5.2 Definition of Cell Type-Specific versus Shared Genes
We classified genes as cell type-specific or shared via the Shannon entropy across the five
cell types. Gene expression data was downloaded from BLUEPRINT [18]. Since this gene ex-
pression is calculated by MMSEQ, we took exponentials so that transcript quantification was
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comparable to RPKM. For each gene, we calculated the normalized gene expression as the gene
expression in one cell type divided by the sum of the gene’s expression across all five cell types.
Next, we calculated the entropy (defined as the distance to log2(K), where K=5 is the number
of cell types) using the relative gene expression across cell types. We defined cell type-specific
genes as those with entropy ą 0.5 and gene expression ą 1, in the respective cell type, and shared
genes across cell types as those with entropy ă 0.1. Approximately 534-1,814 genes are cell type-
specific, depending on cell type (Figure B.1f), and 1,476 genes meet the shared gene criteria.
3.5.3 Defining SIPs
We first calculated the cumulative interaction scores for each promoter-containing anchor
bin (bait) in the pcHi-C data [65], in each cell type. For each bait, the cumulative interaction
score is the sum of the CHiCAGO scores of significant interactions (CHiCAGO score ě 5, as
informed by Cairns et al. [15]). Interactions with CHiCAGO score ă 5 are not included in the
cumulative interaction score. For each cell type, we ranked the cumulative interaction scores. By
finding the inflection point of the ranked baits, we defined super interactive promoters (SIPs) as
those baits with extremely high cumulative interaction scores. This approach is similar to how
super-enhancers are defined [63]. SIPs are approximately the top 7.5% of cumulative interaction
scores.
3.5.4 SIP PIRs Overlap with Relevant GWAS Variants
In each cell type, for every SIP, we determined if at least one PIR overlapped with a relevant
blood cell trait variant, using summary statistics from the latest two GWAS studies on blood cell
traits, including GWAS variants identified in European samples [130] as well as non-European
and trans-ethnic analyses [19]. Phenotypes (i.e., relevant traits) considered for each cell type are
as follows: any red blood cell trait (HCT, HGB, MCH, MCHC, RBC, RDW) for erythrocytes,
MONO or WBC for macrophages/monocytes, PLT or MPV for megakaryocytes, LYM or WBC
for naive CD4 T-cells, and NEU or WBC for neutrophils. Next, for each cell type, we randomly
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sampled non-SIPs (where n sampled is the number of SIPs in the respective cell type) and de-
termined if at least one PIR overlapped with a relevant variant. This sampling procedure was
repeated 100 times, and the median number of non-SIPs with a PIR overlapping a relevant variant
was recorded. Fisher’s exact test was then used to compute odds ratios and 95% confidence inter-
vals for the odds of a SIP with variant overlap compared to a non-SIP with variant overlap. The
same procedure was conducted for cell type-specific SIPs.
To construct SIP subnetworks, we only considered the conditionally independent GWAS vari-
ants from Vuckovic et al. [130]. Consequently, each SIP subnetwork has PIRs that each overlap
with a relevant statistically independent variant, as well as a cell type-specific ATAC-seq peak
[126]. We identify SIP subnetworks for each of the following cell type/phenotype combinations:
erythrocytes (HCT (2), HGB (2), MCH (7), MCHC (3), RBC (4), RDW (11)), macrophages/-
monocytes (MONO (5), WBC (1)), megakaryocytes (PLT (14), MPV (10)), and naive CD4 T-
cells (LYM (15), WBC (2)). When removing the constraint of PIR overlapping with ATAC-seq
data for neutrophil SIPs, as it is unavailable, we identify neutrophil SIP subnetworks for NEU
(16) and WBC (22).
3.5.5 Fold Enrichment Test for Highly Expressed Genes Among SIP Genes
Gene expression was ranked from highest (1st) to lowest (5th) quintile in each cell type. For
each cell type, we calculated the proportion of SIP genes with rank r out of the total number of
genes with rank r. Fold enrichment was then calculated relative to the group with the lowest gene
expression (5th) and the significance level was obtained through a Chi-square test for proportions
(for each cell type).
3.5.6 Comparing Gene Expression Levels in SIP Genes
We downloaded gene expression data for all tissues from the GTEx portal. For comparison
to our blood cell types of interest, we used exponentiated BLUEPRINT gene expression [18]
for erythrocytes, macrophages/monocytes, megakaryocytes, naive CD4 T-cells, and neutrophils.
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For each of the shared SIP genes, we computed the mean gene expression across all five blood
cell types and the mean gene expression across all other tissues (non-blood cells). Next, we
partitioned the shared SIP genes into percentiles based on the ranked mean gene expressions
in blood cells (Figure B.5a-b), and the ranked mean gene expressions in other tissues (Figure
B.5c-d). We followed a similar computational process for the cell type-specific SIP genes. For
each set of cell type-specific SIP genes, we partitioned the genes into percentiles based on the
ranked gene expression in the respective cell type (Figure B.6a-b), and the ranked mean gene
expressions in other tissues (Figure B.6c-d).
3.5.7 Partitioned Heritability for Cell Type-Specific SIP Genes
We leveraged linkage disequilibrium score regression (LDSC) [12, 40] using the cell type-
specific SIP PIRs to partition the SNP heritability for 15 blood cell traits from trans-ethnic
GWAS summary statistics [19]. LDSC jointly models 75 baselines annotations consisting of cod-
ing, UTR, promoter, and intron regions, histone marks, DNase I hypersensitive sites, ChromH-
MM/Segway predictions, regions that are conserved in mammals, super-enhancers, FANTOM5
enhancers, and LD-related annotations (recombination rate, nucleotide diversity CpG content,
etc.) that are not specific to any cell type.
3.5.8 Supplemental Note 1.
Neutrophils were excluded from the SIP and ATAC-seq peak analysis. The Ulirsch et al.
[126] ATAC-seq data used in this analysis does not include neutrophil ATAC-seq. Chen et al.
[20] isolated neutrophils from two healthy donors’ blood. Peak calling of this data (performed by
MACS2 narrow peak mode with default parameters q 0.01 nomodel shift 0) resulted in „2,000
neutrophil ATAC-seq peaks, which is 1-2 orders of magnitude smaller than expected based on
ATAC-seq in other hematopoietic cell types and consistent with the findings of Chen et. al who
note that neutrophils have fewer chromatin accessibility peaks than do cell types with comparable
sequencing depths and alignment rates. Since neutrophils are terminally differentiated cells with
57
a short lifespan and the accessible chromatin peaks are not associated with usual euchromatin
marks, it is possible that ATAC-seq peaks are not enriched or relevant for neutrophil traits. We
also note that ATAC-seq data from monocytes was used for analyses involving the macrophage/-
monocyte SIPs.
3.5.9 Abbreviations of Blood Cell Traits
HCT = Hematocrit; HGB = Hemoglobin; MCH = Mean Corpuscular Hemoglobin; MCHC =
MCH Concentration; MCV = Mean Corpuscular Volume; RBC = Red Blood Cell Count; RDW
= RBC Distribution Width; BASO = Basophil Count; EOS = Eosinophil Count; LYM = Lympho-
cyte Count; MONO = Monocyte Count; NEU = Neutrophil Count; WBC = White Blood Cell
Count; PLT = Platelet Count; MPV = Mean Platelet Volume
3.5.10 Web Resources
Human Protein Atlas (HPA), https://proteinatlas.org/
Genotype-Tissue Expression (GTEx Portal), https://gtexportal.org/
Online Mendelian Inheritance in Man (OMIM), https://omim.org/
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CHAPTER 4: PREDICTING THE IMPACT OF NON-CODING GENETIC VARIANTS
4.1 Introduction
As discussed in Section 1.1, Genome-wide association studies (GWAS) have discovered
thousands of genetic variations that are associated with hundreds of complex human diseases and
traits [84]. However, a vast majority of these GWAS variants reside in the non-coding regions,
and the mechanisms of how these variants contribute to gene dysregulation remain obscure [88].
Although there has been rapid progress in identifying potential regulatory elements in the human
genome [26], studies to pinpoint the function of genetic variants, especially in disease-specific
context, have been lacking.
Most variants associated with human disease lie in non-coding genomic regions, making it
difficult to directly evaluate functional impact. To address this challenge, several computational
methods have been developed to prioritize causal non-coding risk variants through integrating
various genomic and epigenomic annotations (see Section 1.6). A recently developed network-
based approach, ARVIN (Annotation of Regulatory Variants using Integrated Networks) com-
bines sequence-based and network-based features to provide a computational framework for
predicting causal non-coding variants in a disease/trait-specific context [50].
ARVIN and other recent advances in gene regulatory networks have suggested how poten-
tially causal variants exert their effect. While it is desirable to infer such molecular causal paths
specific to each disease/trait, for some traits, due to sample size or shared biology, it may help
to group related diseases and traits to borrow information from each other, where grouping can
involve more closely related traits (finer resolution) or more loosely relevant ones (coarser res-
olution). Further, evidence of a variant being at least nominally significant in multiple related
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diseases may suggest a higher chance for that variant to be causal. To improve upon ARVIN and
to allow for simultaneous modeling of related diseases/traits, we developed MARVIN (multi-
disease/trait ARVIN) to predict the impact of risk variants at a cascade of resolutions. We demon-
strate that by aggregating information from related diseases or traits, MARVIN improves the
predictions of non-coding genetic variants and allows us to better study how they can influence
the gene regulatory network in a tissue-specific or disease-specific manner.
In this study, we focus on risk variants for four brain traits, including three neuropsychiatric
traits (bipolar (BIP), depression (DEP), and schizophrenia (SCZ)) and one neurocognitive trait
(Altzheimer’s and other dementias (AD/D)), which presents neuropsychiatric symptoms. Psychi-
atric disorders are of great interest to public health given their prevalence and association with
increased rates of mortality as well as high cost [54]. Consequently, numerous GWAS have been
conducted, revealing the genetic architecture of psychiatric disorders [55, 122]. However, the
number of loci discovered through GWAS is largely influenced by the sample size (i.e., increas-
ing the sample size will lead to more identified loci) [54, 123]. Further, a deeper understanding of
the functional genetic architecture of psychiatric traits is necessary to form hypotheses regarding
how these loci interact with gene networks [122]. Efforts from consortiums such as PsychEN-
CODE [25] and BRAIN Initiative Cell Census [36] have produced and integrated various types
of functional genomic data from human brain, at the tissue and single-cell levels, for neurotypical
controls and psychiatric cases. Given that most variants that contribute to common psychiatric
disorders lie in non-coding regions, and since brain tissue is highly heterogeneous, tissue- and
cell type-specific functional data is crucial to learning how psychiatric risk variants exert their
effect [122, 136].
Notably, Sullivan et al. report that for ten psychiatric disorders examined (including BIP,
DEP, and SCZ), 22 out of 241 loci with significant association are associated with at least 2
psychiatric disorders [122]. They also note that many loci, though disease specific, increase risk
for multiple disorders. Due to the complexity of psychiatric disorders and the knowledge gap
regarding their causal risk variants, we believe that constructing trait-specific GRNs with tissue-
60
and cell type-specific functional data, while incorporating pertinent information from related
traits, will help prioritize psychiatric risk variants and clarify GWAS findings.
4.2 Results
4.2.1 Selected Variants
We first examine the relationships between variants associated with AD/D, BIP, DEP, and
SCZ. ARVIN assumes that the input variants reach genome-wide association significance (e.g.,
GWAS p-value ă 5e-8). However, many traits do not have variants meeting this stringent criteria,
which is largely influenced by GWAS sample size. For example, while there are 108 AD/D SNPs
with p-value ă 5e-8, there are 0 BIP, 1 SCZ, and only 19 DEP variants with p-value ă 5e-8.
Therefore, we took a different approach to selecting which variants to consider for predicting
causal probability.
For each trait, we selected variants with moderate to high association (p-value ă 1e-4) with
the corresponding trait (i.e., primary trait) and at least some association (p-value ă 0.05) with
a related trait (i.e., secondary trait), along with other variants in high LD (Methods). Figure 4.1
displays the number of selected variants as well as how they are shared across the four traits. We
find that a majority of selected variants are unique to the primary trait. In other words, very few
selected variants (less than 1%) have moderate to high GWAS significance in more than one of
AD/D, BIP, DEP, and SCZ. It is interesting to note that the number of variants shared between
traits reflects the genetic correlation between those traits. For example, the genetic correlation is
greatest between BIP and SCZ (0.794) and we find that these traits also share the most selected
variants (47). Further, there is no genetic correlation nor shared variants between AD/D and the
other three traits. Details on the genetic correlations between all four traits obtained from Bulik-
Sullivan et al. [11] can be found in Table C.1. We also note that when only considering the subset
of selected variants that are lead SNPs, the only shared variants are between BIP and SCZ (3),
DEP and SCZ (2) and BIP and DEP (1).
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Figure 4.1: Most selected variants are unique to the primary trait. (AD/D = Altzheimer’s and
other dementias; BIP = bipolar; DEP = depression; SCZ = schizophrenia)
We can further examine the selected variants by their secondary traits (Figure 4.2, Figures
C.1-C.4). For instance, the rightmost bar of Figure 4.2 represents the selected variants where
there is moderate to high association with SCZ, and at least some association with DEP. We again
find that the strength of genetic correlation is reflected in the composition of our selected variants.
As mentioned previously, there is no genetic correlation between AD/D and the other traits, and
accordingly we observe that when AD/D is the secondary trait, it results in the fewest variants.
Since there is no strong evidence of relatedness between AD/D and the neuropsychiatric traits,
and it appears that not much value is gained by including AD/D, we proceed with this study only
considering BIP, DEP, and SCZ.
4.2.2 ARVIN
Next, for each neuropsychiatric trait (BIP, DEP, and SCZ), we ran ARVIN for our selected
variants as well as for sets of control variants (Methods); Figure 4.3 shows the distribution of
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Figure 4.2: Strength of genetic correlation is reflected in composition of selected variants. For
each trait, the total number of selected variants by secondary trait is shown by bar height. The
strength of genetic correlation is reflected by bar opacity. (AD/D = Altzheimer’s and other
dementias [grey]; BIP = bipolar [blue]; DEP = depression [green]; SCZ = schizophrenia [pink])
ARVIN scores in each case. We find that, for each trait, our selected variants have significantly
higher ARVIN scores than the control variants (Wilcoxon p-value ă 3.8e-5, Table C.2). However,
we also find that the magnitude of difference between the selected and control variants is less
than expected (0.16 on average). These results suggest two things about ARVIN that could be
improved.
First, these results provide evidence that the model would benefit from directly including
measures of association strength between trait and variant. Without considering association
strength, ARVIN assumes that every variant is highly associated with the trait and considers each
potential variant equally likely a priori, lending to less differentiation in predicted scores between
selected and control variants. As a result, ARVIN is best suited to predict the probability of a
variant being causal for a particular trait, conditional on that variant being highly associated with
the trait. However, as discussed previously, many traits (including the ones presented here) have
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Figure 4.3: ARVIN scores of selected variants are significantly higher than control variants.
Selected bipolar (BIP [blue]), depression (DEP [green]), and schizophrenia (SCZ [pink]) variants
have significantly higher ARVIN scores (Wilcoxon p-value ă 3.8e-5) than the same number of
variants, in the corresponding trait, drawn at random (control). (BIP = bipolar; DEP = depression;
SCZ = schizophrenia)
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very few, if any, SNPs meeting this stringent criteria. By incorporating association strength in the
model, we can obtain the probability of a variant being causal for a particular trait, without any
assumption about its association strength with the trait. This approach will consequently allow us
to better predict causal probability for variants with moderate GWAS significance, which are also
of great interest.
Second, these results motivate jointly modeling multiple traits. Recall that the selected vari-
ants have moderate GWAS significance in the primary trait, and some significance (not necessar-
ily strong) in the secondary trait. The ARVIN score distributions in Figure 4.3 suggest there is
some value in considering information from related traits in separate models, but simultaneously
modeling related traits in a unified framework would increase the power to differentiate between
causal and non-causal variants.
4.2.3 Simulations
There are very few variants known to be causal for a particular disease/trait. For instance, a
list of known risk SNPs located in transcriptional enhancers published by Gao et al. [50] only
includes 15 variants related to 10 diseases/traits. This gap in our knowledge of causal variants
motivates the need for methods that can accurately predict them, but consequently also results in
extremely small sets of variants that can be used to train a model to distinguish between true risk
variants and negative control variants. Consequently, we chose to simulate data where we can
define and know which variants are causal or not. We simulated data under the scenario of three
related traits, using real data annotations and functional data, in order to construct networks and
train a classifier (Methods).
4.2.4 MARVIN
We will construct two types of disease/trait-relevant gene regulatory networks (GRNs): one
for a single disease/trait, and one for groups of related diseases/traits. The first individual network
type will be constructed following the ARVIN framework. The second group network type will
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be constructed following a similar approach, but will also capture and model the relationships
between the variants and genes of related diseases/traits. For both network types, ARVIN’s five
network features (betweenness centrality, closeness centrality, pagerank centrality, weighted
degree, and module score) will be calculated for each variant. We will then combine the network
features and sequence-based features in order to train an ARVIN-like random forest classifier.
In order to allow for modeling of the second network type, we will expand the ARVIN method
to allow for GRNs of related diseases/traits. Through jointly modeling related disease/traits,
we will derive additional features that encapsulate the unified network. Our multi-disease/trait
ARVIN classifier (termed MARVIN) is a flexible hierarchical, network-aided predictive modeling
framework to predict variant impact specific to a disease/trait, or a group (at varying resolutions)
of diseases/traits.
We will evaluate the performance of MARVIN by comparing its variant impact predictions
across multiple resolutions (i.e., single trait network vs multi-trait network). We expect that
by incorporating network information from related traits, MARVIN will have better power to
predict the causal probability of variants than ARVIN. Further, we will generate a prioritized list
of candidate risk variants by applying MARVIN to a compendium of variants associated with a
diverse set of diseases.
4.2.5 Cell type-specific MARVIN
ARVIN could also be improved by utilizing cell-type specific input data. We will consider
expanding the underlying ARVIN framework in two ways to construct cell type-specific GRNs.
First, for the sequence-based features, we propose combining genomic features and cell type-
specific transcriptomic and epigenomic features, rather than a subset of GWAVA and FunSeq2
features as used by ARVIN. Second, for the network-based features, we propose using single-
cell-based data to construct cell type-specific gene regulatory networks. Specifically, we will use
cell type-specific enhancers and cell type-specific enhancer-promoter interactions for the node
and edge weights, respectively. For the functional interaction weights, ARVIN currently uses Hu-
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manNet interaction networks [74], which are not cell type- and disease/trait-specific. To construct
cell type-specific and disease relevant functional gene interaction networks, we intend to leverage
single-cell RNA-seq (scRNA-seq) data, using mutual information between all pairs of genes. We
will also consider using scRNA-seq data from matched case and control samples to determine
cell type-specific differentially expressed genes. However, this data remains challenging to col-
lect, particularly for a wide range of diseases/traits; we will use bulk transcriptome data as done
previously, if the single-cell data is not available.
For each disease/trait, we will construct cell-type-specific GRNs using cell types from the
organ(s) known to be affected in the given disease and apply MARVIN to the variants of interest.
For a disease that affects multiple cell types, we will compute an aggregated probability score
by applying the Fisher’s product rule to the set of probabilities produced by MARVIN based on
each cell type-specific GRN. This aggregated probability score will be used as the final score for
each variant in the given disease/trait. We will evaluate the performance of this cell type- and
disease/trait-specific GRN approach relative to the original disease/trait-specific GRN approach.
We expect that the predictions of how likely a genetic variant is a risk variant will be more ac-
curate when using cell type- and disease/trait-specific GRNs than when only using disease/trait-
specific GRNs.
4.3 Discussion
The ARVIN method provides a valuable framework for incorporating disease/trait-specific
GRNs into the prioritization of causal variants. Gao et al. have shown that network-based fea-
tures derived from these GRNs, in conjunction with sequence-based features, improve the detec-
tion of non-coding risk variants [50]. Moreover, they also showed that disease-specific networks
have more discriminative power than non-disease-specific networks in distinguishing true risk
variants from control variants. Here, we expand upon this framework by developing MARVIN,
to predict the impact of non-coding regulatory variants on effector genes relevant to groups of
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diseases/traits at varying resolution. We further enhance this framework with cell type-specific
sequence and network features.
We expect that the results from this study will show increased power to predict causal vari-
ants when modeling related diseases/traits simultaneously over modeling each disease/trait sep-
arately. This feature of MARVIN will be especially beneficial for diseases/traits where sam-
ple sizes are small or difficult to obtain. We also conjecture that constructing cell type- and
disease/trait-specific GRNs will further improve prediction accuracy, particularly in cases where
bulk sequencing data masks effects from individual cell types.
MARVIN will be implemented as easy to use software, and freely available. We will also
apply MARVIN to disease/trait-associated genetic variants to generate a ranked catalogue of risk
variants for a compendium of diseases/traits. We anticipate that MARVIN and our precomputed
variant scores will be a useful resource for many researchers.
We note that the performance of MARVIN can be affected by the quality of GRN and train-
ing data. As more experimental data on molecular interactions become available, we will evaluate
the accuracy of our constructed GRNs using those orthogonal data. In addition, as more variants
are experimentally validated, the training set will be improved.
4.4 Methods
4.4.1 Selected Variants
GWAS summary statistics used in this study were downloaded from the UK Biobank (UK
Biobank) [14] instance of PheWeb (https://pheweb.org/UKB-SAIGE/) [47]. The sum-
mary statistics data provided by PheWeb is resultant of GWAS analysis of 1,403 ICD-based traits
using SAIGE. We downloaded this UKB GWAS summary statistics data for bipolar (1,064 cases),
depression (11,901 cases), schizophrenia (571 cases), and shared control samples (365,476 con-
trols), in addition to data for dementias (956 cases and 402,383 controls).
We determined our selected variants as follows. First, we define SNPs of interest as those
with GWAS p-value ă 1e-4 for a primary trait (e.g., BIP) and GWAS p-value ă 0.05 for a sec-
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ondary trait (e.g., one or more of AD/D, DEP, SCZ). Next, we used TopLD (http://topld.
genetics.unc.edu/) to determine all SNPs in the same LD (r2 ą 0.9) as our SNPs of in-
terest. TopLD is a recently developed resource that utilizes TOPMed whole genome sequencing
(WGS) data to provide a comprehensive representation of genetic variation and their LD pat-
terns. For each trait, our selected SNPs comprises the SNPs of interest as well as those in high
LD. Since there is no genetic correlation between AD/D and each of BIP, DEP, and SCZ [11], we
only focus on the latter three traits in this study. For example, for the information presented in
Figure 4.3, when BIP is the primary trait, the secondary traits considered are only DEP and SCZ.
Using this selection approach, we obtain 1,435, 1,654, and 1,640 unique selected variants for BIP,
DEP, and SCZ, respectively. When we compare our selected variants to the corresponding set
of variants not conditioned on the significance in a secondary trait (i.e., the variants with GWAS
p-value ă 1e-4 in the primary trait along with those in high LD), we find that they account for
61%, 50%, and 63%, in BIP, DEP, and SCZ, respectively. This suggests that there is value in
using information in related traits.
4.4.2 Control Variants
For each trait, we randomly sampled GWAS variants such that there were as many control
variants as the selected variants used for ARVIN input (GWAS SNPs of interest + SNPs in the
same LD). This sampling was repeated ten times for each trait (i.e., ten control variant sets per
trait). Using the same trait and tissue-specific input data as the selected variants, we ran ARVIN
for each of the control sets for their respective traits. Figure 4.3 shows the distribution of ARVIN
scores for the selected variants and the first control variant set, for each trait.
4.4.3 ARVIN
We will briefly summarize the ARVIN method here, though complete details can be found in
Gao et al.’s 2018 Nature Communications paper [50]. For each disease, ARVIN first constructs
an integrative GRN. The network consists of two types of nodes (genes and SNPs/variants) as
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well as two types of edges (gene-gene interactions (functional interaction [FI] edge) and SNP-
gene interactions (enhancer-promoter [EP] edge)). Here, SNPs of interest are determined by
the intersection of a lead GWAS SNP’s LD block with a set of enhancers from disease-relevant
tissue/cell types. FI edges are taken from HumanNet [74], a functional gene network of protein
coding genes in humans. EP edges are based on enhancer-promoter interactions predicted by
the IM-PET algorithm [59] using tissue/cell type-specific ChIP-seq and gene expression data.
Using these nodes and edges, five network-based features are calculated that are designed to
evaluate the topological importance of the target genes. ARVIN incorporates these network-based
features with sequence-based features used by GWAVA [105] and FunSeq2 [43] (182 genomic
and epigenomic features in total) to train a random forest classifier for predicting risk variants.
Consequently, probability scores for a set of SNPs can be obtained from the trained model to
prioritize risk variants.
4.4.4 GWAVA and FunSeq2
GWAVA (Genome-wide annotation of variants) [105] and FunSeq2 [43] each use a wide
range of annotations to prioritize and predict the functional impact of non-coding variants. GWAVA’s
annotation sources include those pertaining to open chromatin, transcription factor binding, hi-
stone modifications, genome segmentation, conservation, genic context, and sequence context,
to predict the functional impact of non-coding variants. We obtained GWAVA feature values by
uploading our selected variants’ rs numbers to the GWAVA web portal (https://sanger.
ac.uk/sanger/StatGen_Gwava). FunSeq2 was designed to prioritize cancer somatic vari-
ants, in particular. In addition to the types of annotation sources used by GWAVA, FunSeq2 also
includes those pertaining to RNA polymerase binding, CpG islands, and human variation. We
obtained FunSeq2 feature values by uploading our selected variants’ coordinates to the FunSeq2
web portal (version 2.10) (http://funseq2.gersteinlab.org/).
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4.4.5 Enhancer-Promoter (EP) Interaction Scores
To calculate EP interaction scores, we utilized the 75,531 high-confidence regulatory chro-
matin interactions identified by Giusti-Rodriguez et al. in adult brain cortex Hi-C data [55]. This
set of interactions have p-value ă 2.31x10-11 and anchors overlapping enhancers or promoters.
Enhancers were defined as the intersection of eHi-C HindIII fragment within an anchor, open
chromatin, and either a H3K27ac peak or a H3K4me3 peak overlapping the start site of a brain-
expressed transcript; they defined promoters as brain-expressed transcripts overlapping open
chromatin. Although we know the anchors are either enhancers or promoters, they were unla-
beled in the data. Accordingly, we first matched one anchor to a known promoter region from
GENCODE [42], and marked the other unmatched anchor as the enhancer region in order to de-
fine EP interactions as required by ARVIN. We then calculated an EP interaction score for each
interaction by scaling the ratio of observed to expected Hi-C contact counts to fall within 0.8-1.0.
The lower bound (0.8) was chosen to be relatively high due to the high confidence of these EP
interactions.
4.4.6 Differential Gene Expression (DE) Data
ARVIN requires differential gene expression information (gene and corresponding p-value)
from case vs control comparison in disease-relevant cells/tissues. We downloaded DE data for
BIP and SCZ from Gandal et al. [49]. This data was generated from frontal and temporal cortex
brain samples and is part of Freeze 1 and 2 of the PsychENCODE Consortium dataset. Gandal et
al. identify 1,119 differentially expressed genes in BIP, and 4,821 differentially expressed genes
in SCZ (Benjamini-Hochberg p-value ă 0.05). For DEP, we downloaded DE data from Wu et al.
who performed a differential expression meta-analysis across multiple brain regions for major
depressive disorder (MDD) cases vs controls [137]. Wu et al identified 55 differentially expressed
genes in DEP (Bonferroni p-value ă 0.05).
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4.4.7 Simulations
We first downloaded TopMed (freeze 8) variants annotated using the WGSA pipeline [81].
We then selected 23 common annotations that partly determine if a variant is causal or not. These
annotations include, among others, CADD scores, fathmm XF scores, as well as functional-
ity scores (Genoskyline-Plus scores) and H3K27ac narrow peaks in several brain tissues from
Roadmap Epigenomics Project. We found high correlations between pairs of annotations per-
taining to the same tissue (e.g., Roadmap E067 GenoSkyline-Plus scores and Roadmap E067
H3K27ac narrow peaks). Therefore, we averaged the two scores for the same tissue, where ap-
plicable. We also noticed that the GenoSkyline-Plus scores for E081 (fetal brain male) and E082
(fetal brain female) are strongly correlated. We again averaged the two annotation scores to create
a new variable named Fetal Brain. The correlation plot of the 15 features is shown in Figure C.5.
Using these annotations, we constructed a causal variant score for each variant by summing
up the 15 standardized annotation features and adding a random term, where a higher score indi-
cates more evidence of the variant being causal. For the purposes of our simulations, we defined
positive controls as those with high causal variant scores (top 13%) and then defined the remain-
ing variants as negative controls. We also restrict all variants to reside in an enhancer region, as
is done in ARVIN. Enhancer regions from fetal brain were downloaded from EnhancerAtlas 2.0
(http://enhanceratlas.org/) [52, 51]. Similar to the findings of GWAVA [105], Fun-
seq2 [43], and ARVIN [50], we find differences in the distributions of several of the annotations
used in the causal variant score, between the positive and negative control variants (Figure C.6).
However, due to the complexity of causal variants, no individual annotation can provide enough
discriminative evidence to accurately distinguish between positive and negative control variants.
Next, we randomly split the positive and negative control variants into three groups, repre-
senting three related traits (e.g., T1, T2, and T3). For each trait, there are „2,000 positive controls
and 14,000 negative controls. We consider that T1 is moderately correlated with T2 (genetic
correlation = rg = 0.6), T1 is highly correlated with T3 (rg = 0.8), and T2 is weakly correlated
with T3 (rg = 0.4). To determine which variants are shared between traits, we simulated Bernoulli
72
trials, where the probability of “success” is informed by the genetic correlation between traits.
We then sample from a random multivariate normal distribution to generate causal variant scores
for the shared traits. Here, the mean is the original causal variant score, and the covariance matrix
has variance = 1 along the diagonal, and covariance = rg for the remaining entries. The shared
variants were then classified as positive or negative based on their simulated causal variant scores
(using the original threshold). This procedure resulted in a total of 2,136, 1,990, and 1,921 posi-
tive controls for T1, T2, and T3, respectively. There are 1,209 positive controls shared between
T1 and T2, 852 shared between T1 and T3, 540 shared between T2 and T3, and 480 shared be-
tween all three traits. Though greater in number, the negative control variants are shared in simi-
lar proportions.
Using min-max normalization, we scaled the causal variant scores to represent causal proba-
bilities. Then, for each variant, we simulated three Uniform(0,1) random variables (one for each
trait). If the uniform random variable was less than the causal probability, we defined that vari-
ant as truly causal. This procedure resulted in a total of 645, 557 and 581 causal variants for T1,
T2, and T3, respectively. There are 319 causal variants shared between T1 and T2, 379 shared
between T1 and T3, 238 shared between T2 and T3, and 135 shared between all three traits.
To incorporate the GWAS summary statistics while accounting for LD, we simulated three
phenotypes of 99,990 randomly drawn UK Biobank participants with primary European ancestry
[14], representing the three traits we considered. Genotype imputation was performed via the
Michigan Imputation Server with TOPMed freeze 5b reference panel. Then, we drew the effect
sizes of the three traits from a multivariate normal distribution with mean (1,1,1) and covariance
matrix the same as before. The corresponding standard errors of effects were treated as indepen-
dent and simulated from a Uniform(0,0.5) distribution for each trait. After determining the effect
size of each variant, we then simulated the effect of each variant for each subject from indepen-
dent normal distributions. Each individual’s phenotype was generated by summing up all the
single variant effects and adding a random error from Normal(0,1).
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Based on the defined sets of causal variants for each trait, we next determined the causal
genes. For each causal variant loci, we selected genes from some gene networks/pathways in
HumanNet [74]. DE data was simulated accordingly, and EP interaction data was taken from
high-confidence regulatory chromatin interactions identified by Giusti-Rodriguez et al. in fetal
brain cortex Hi-C data [55].
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CHAPTER 5: CONCLUSION
Genome-wide association studies (GWAS) have identified thousands of genetic variants that
are associated with various human diseases and traits [13]. However, the mechanisms by which
these variants exert their effect and the target gene(s) for each identified variant are largely un-
known [95]. Evidence suggests that many GWAS variants may contribute to disease pathogenesis
by affecting the regulatory mechanisms of gene transcription [16, 48]. It is also believed that
chromatin spatial organization plays a critical role in such genome functions, including transcrip-
tion regulation and DNA replication [8, 28, 78, 91]. For instance, chromatin loops join enhancers
and promoters to allow distal enhancers to influence the transcription of their target genes, many
of which are far away in one-dimensional genomic distance [111, 116, 146]. Further, it has been
demonstrated that high resolution 3D genome-wide analysis can annotate GWAS SNPs and link
these variants to their target genes [124, 65, 136, 146]. This can be accomplished through chro-
mosome conformation capture technologies, such as Hi-C.
Due to the potential regulatory nature of chromatin loops, there is significant interest in de-
termining if observed chromatin contacts are functional or due to random looping. Consequently,
there are several existing methods that seek to determine whether the observed contact frequency
is significantly higher than expected from random chromatin collision. In particular, to identify
statistically significant long-range chromatin interactions from Hi-C data, most existing methods
assume that all chromatin interactions are statistically independent. However, the spatial depen-
dency of neighboring chromatin interactions is non-negligible in high resolution Hi-C data, as
loci are more likely to interact with each other if adjacent loci exhibit high interaction frequency.
In Chapter 2, we develop HiC-ACT, an aggregated Cauchy test (ACT)-based approach, to im-
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prove the detection of chromatin interactions by post-processing results from methods assuming
independence. To benchmark the performance of HiC-ACT, we re-analyzed deeply sequenced
Hi-C data. Our results demonstrate advantages of HiC-ACT in improving sensitivity with con-
trolled type I error. By leveraging information from neighboring chromatin interactions, HiC-
ACT enhances the power to detect interactions with lower signal-to-noise ratio and similar (if
not stronger) epigenetic signatures that suggest regulatory roles. We further demonstrate that
HiC-ACT peaks show higher overlap with known enhancers than Fit-Hi-C/FitHiC2 peaks. By
identifying statistically significant long-range interactions with enhanced statistical power and
improved computational efficiency, HiC-ACT can improve our knowledge regarding regions
with regulatory potential, and aid attempts to establish links between cis-regulatory regions and
their target genes. HiC-ACT can also be utilized or extended in other applications. For instance,
we could investigate identifying summits from the HiC-ACT “smoothed” peak results, which
may help to identify the most important chromatin interactions. In addition, the HiC-ACT frame-
work could be extended for application to single cell Hi-C data, where the data is sparse and can
potentially benefit even more from the aggregated Cauchy test.
Existing studies of chromatin conformation have primarily focused on potential enhancers
interacting with gene promoters. By contrast, the interactivity of promoters per se, while equally
critical to understanding transcriptional control, has been largely unexplored, despite promoters
being equally critical to understanding transcriptional control. Further, promoter interactomes
are tissue- and lineage-specific, so there has been growing interest in studying promoter interac-
tomes in a cell type-specific manner. However, due to the complexity and sparsity of Hi-C data,
it is difficult to identify statistically significant chromatin interactions between distant genomic
sequences at fine resolutions even with tens of billions of pairwise reads produced [114]. Further,
ultra-deep sequencing is costly and likely to generate redundant reads, leading to Hi-C library
saturation [73]. In order to identify interactions between individual restriction fragments, such as
those containing a promoter, promoter capture Hi-C (pcHi-C) was developed as an extension of
the Hi-C technique. pcHi-C combines target enrichment and sequencing to enable the genome-
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wide detection of distal promoter-interacting regions (PIRs). Importantly, pcHi-C analysis can be
used to link non-coding regulatory variants to their target genes and to provide insight into gene
expression control and the function of non-coding disease-associated variants [65, 92, 113, 114].
In Chapter 3, we leverage promoter capture Hi-C data across a compendium of blood lineage
cell types to identify and characterize cell type-specific super-interactive promoters (SIPs). Blood
cells are highly relevant tissues for many complex phenotypes, including thrombosis, infectious
disease susceptibility, and autoimmune conditions [2, 80]. Since the various blood cell types play
different roles in cell generation and function, and correspond to different phenotypic traits, it is
important to study them in a cell type-specific manner. Consequently, understanding the interac-
tions of gene promoters and their regulatory regions in specific blood cell types, as opposed to
simple analysis of whole blood, can lead to improved annotation of GWAS identified loci and
their target genes. Therefore blood cell SIPs are of broad interest for understanding gene regula-
tion and its connection to disease risk. Notably, we find that promoter-interacting regions (PIRs)
of SIPs are more likely to overlap with cell type-specific ATAC-seq peaks and GWAS variants
for relevant blood cell traits than PIRs of non-SIPs. Further, SIP genes tend to be expressed at
a higher level in the corresponding cell type, and show enriched heritability of relevant blood
cell trait(s). Importantly, this analysis shows the potential of using promoter-centric analyses of
chromatin spatial organization data to identify biologically important genes and their regulatory
regions. This chapter presents important findings governing the orchestrated transcriptional con-
trol in blood lineage cell types, and provides valuable insights and resources for the interpretation
and follow-up of GWAS findings of many blood cell-related complex traits. Some follow-up
studies could be also conducted to assess enhancer function and redundancy behind SIP and
non-SIP genes, using recently developed methods such as Mosaic-seq [138] and CRISPRpath
[103]. Moreover, the combinatorial effects of enhancers related to SIP genes could be studied by
applying some assays that disrupt multiple enhancers simultaneously [27].
A vast majority of genetic variants associated with complex diseases and traits reside in the
non-coding regions of the genome, and the mechanisms of how they contribute to gene dysreg-
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ulation remain obscure [95, 88]. Although there has been rapid progress in identifying potential
regulatory elements in the human genome, studies to pinpoint the function of genetic variants,
especially in a disease-specific context, have been lacking. To address this challenge, several
computational methods have been developed to prioritize causal risk variants through integrating
various genomic and epigenomic annotations (including chromatin capture data, as described
in chapters 2 and 3). These methods, however, dont account for the interactions, for example,
between transcription factors and their target genes, or among target genes in the same pathway,
despite disease-perturbed gene networks being vital to the development of disease. Since the
effects of non-coding variants are transcriptionally integrated in a regulatory network and molec-
ular networks have been shown to improve inference accuracy, a network-based approach also
should be an effective strategy to identify causal variants [50, 98]. Moreover, phenotype-relevant
network-based information has been largely ignored for predicting the impact of non-coding
variants. While GWAS has helped us understand the genetic architecture of certain diseases and
traits, a deeper understanding of the functional genetic architecture is necessary to form hypothe-
ses regarding how these GWAS identified loci interact within gene networks.
In Chapter 4, we propose MARVIN (Multi-disease/trait Annotation of Regulatory Variants
using Integrated Networks), a method to predict the impact of non-coding regulatory variants
on effector genes relevant to groups of diseases/traits at varying resolution. By constructing
disease/trait-specific gene regulatory networks and simultaneously modeling related diseases,
MARVIN has increased power to accurately predict causal variants. We also outline how the
MARVIN framework can be enhanced through utilizing cell type-specific sequence and network
features to further improve prediction accuracy, particularly in cases where bulk sequencing data
masks effects from individual cell types. We anticipate that MARVIN will be a useful tool for
prioritizing GWAS findings. It is important to note that MARVIN and other current models to
predict variant impact are heavily restricted by the extremely small number of established non-
coding disease-causing variants. More and higher quality data, particularly regarding the model
outcome (whether a variant is known to be causal for a disease) will help build more robust and
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reliable models. With many large-scale perturbation experiments anticipated, coupled with assess-
ment of disease-related molecular features of established disease-specific causal variants, we may
have such scalable data soon.
The biological and functional insights gained from GWAS have been slow; in particular,
it remains largely unclear how the vast majority of GWAS identified variants contribute to ob-
served phenotypes (i.e., through which genes/gene networks). The first step to address this chal-
lenge is to identify which variants are actually causal for a particular disease or trait. By utilizing
disease/trait-specific gene regulatory networks, MARVIN can predict causal variants and hy-
pothesize their associated target genes. In order to construct networks, MARVIN utilizes various
types of genetic and epigenetic data, including enhancer-promoter interactions. Potentially func-
tional chromatin loops can be obtained by incorporating significant Hi-C interactions (identified
by HiC-ACT or other methods) with functional genomic data, such as histone marks. Moreover,
as shown in our analysis of blood lineage cells, SIP networks demonstrate the complex regula-
tion of promoters, with multiple distinct genetic variants and regions of open chromatin acting
together to regulate genes. These types of studies and analyses, particularly those in a cell type-
or disease-specific context, may elucidate the interactivity between regulatory elements and their
target genes, and link genetic variants to their target genes.
The approaches described throughout this dissertation provide solutions to address the chal-
lenges of characterizing chromatin interactions and linking these 3D chromatin annotations to
genetic results in human populations. By enhancing our understanding of chromatin interactions
and chromatin spatial organization, we can better understand the complex interactions governing
transcriptional control and gain insight into GWAS findings of many complex traits.
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HiC−ACT (p < 0.10)
HiC−ACT (p < 1e−3)
HiC−ACT (p < 1e−6)
HiC−ACT (p < 1e−8)
HiC−ACT (p < p')
Figure A.1: Precision-Recall Curves for calling true peaks. Results for the GM12878 10Kb
data down-sampled to „0.5 billion raw reads (A), „1.0 billion raw reads (B), „1.5 billion raw
reads (C), and „2 billion raw reads (D) are shown with a global p-value of 1.0e-10 for defining
true peaks (using the full „4.9 billion raw read data as truth). Each panel displays the precision
recall curve for peaks called using FitHiC2 (grey) as well as HiC-ACT with various initial filters
(p-value ă 0.10 (orange), p-value ă 1.0e-3 (blue), p-value ă 1.0e-6 (green), p-value ă 1.0e-8
(yellow), p-value ă p1 (pink)). The pink dashed line indicates HiC-ACT applied with our sug-
gested filter (values of p1 can be found in Table A.2). Shapes indicate where a specific global


















































































HiC−ACT (p < 0.10)
HiC−ACT (p < 1e−3)
HiC−ACT (p < 1e−6)
HiC−ACT (p < 1e−8)
HiC−ACT (p < p')
Figure A.2: Precision-Recall Curves for calling true peaks. Results for the GM12878 10Kb
data down-sampled to „0.5 billion raw reads (A), „1.0 billion raw reads (B), „1.5 billion raw
reads (C), and „2 billion raw reads (D) are shown with a global p-value of 1.0e-14 for defining
true peaks (using the full „4.9 billion raw read data as truth). Each panel displays the precision
recall curve for peaks called using FitHiC2 (grey) as well as HiC-ACT with various initial filters
(p-value ă 0.10 (orange), p-value ă 1.0e-3 (blue), p-value ă 1.0e-6 (green), p-value ă 1.0e-8
(yellow), p-value ă p1 (pink)). The pink dashed line indicates HiC-ACT applied with our sug-
gested filter (values of p1 can be found in Table A.2). Shapes indicate where a specific global
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Method HiC−ACT−specific FitHiC2−specific Shared
Figure A.3: Comparing HiC-ACT and FitHiC2 peak calls with Roadmap Epigenomics Consor-
tium enhancers in GM12878 10Kb Hi-C data. HiC-ACT-specific, FitHiC2-specific, and shared
interactions overlapping a super-enhancer (SE)-promoter interaction (left column) or a typical en-
hancer (TE)-promoter interaction (right column) within a specified number of top peaks (ranked
p-values) in the GM12878 data down-sampled to „0.5-2 billion raw reads (rows). The most
significant HiC-ACT-specific interactions show higher overlap with SE-promoter interactions
than the same number of most significant FitHiC2-specific interactions. Performance between the
two methods is comparable for overlap with TE-promoter interactions. In each case, we observe
that the most significant interactions identified by each method are different.
82
Figure A.4: FastHiC and Precision-Recall Curves for calling true peaks. Results for the
GM12878 10Kb data1 for one TAD on chromosome 22 (located at 33,280,000-34,480,000)
down-sampled to „1.0 billion raw reads is shown with a global p-value of 1.0e-12 for defining
true peaks (using the full „4.9 billion raw read data as truth). Each panel displays the precision
recall curve for peaks called using FitHiC2 (grey) and FastHiC (red) as well as HiC-ACT with
various initial filters (p-value ă 0.1 (orange), p-value ă 1.0e-3 (blue), p-value ă 1.0e-6 (green),
p-value ă 1.0e-8 (yellow), p-value ă p1 (pink)). The pink dashed line indicates HiC-ACT applied
with our suggested filter (p1 = 1.7e-4). Each dot indicates where the global p-value threshold
= 1e-12 for defining peaks lies on the curve. We note that FastHiC does not have any p-values
(obtained by subtracting the FastHiC peak posterior probability from 1) less than 1e-12.
As shown in the PRCs, FastHiC underperforms both HiC-ACT and FitHiC2 in this scenario.
FastHiC is designed to call peaks within TADs both for computational reasons and for more
stable estimates of the key inverse temperature parameter that quantifies the degree of spatial
dependency. Since FastHiC is not intended to be used as a chromosome wide peak caller like
FitHiC2, we focused on individual TADs. However, it seems that the default setting of FastHiC
is also not adequately suited for high resolution Hi-C data. We suspect this is due to several
factors, including the number of iterations used and the number of neighboring bin pairs jointly
modeled. We found that even when the number of iterations performed by FastHiC is increased
to 1,000, some parameter estimates did not converge for all TADs. The non-converging issue
exacerbates when we increased the number of neighboring bin pairs to condition on. Similar
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to HiC-ACT, one can determine the neighborhood size in FastHiC. However, unlike HiC-ACT,
all neighbor bin pairs in FastHiC receive equal weight, regardless of their distance to the bin
pair of interest. Similar to the findings reported in the original FastHiC manuscript [140], we
found that increasing the neighborhood size of FastHiC in this example also slightly decreased its
performance.
FastHiC is also computationally much more costly than HiC-ACT. In this example, over a
1.2MB range, FastHiC requires 33 seconds and 607MB memory (300 iterations) while HiC-ACT
requires 6 seconds and negligible memory using the suggested initial p-value filter. We also note
that HiC-ACT is scalable, while FastHiC increases quadratically with the TAD size [140]. If
we used the same data in this example, but expanded our region of interest to include the entire
chromosome rather than a single TAD, FastHiC requires over 5 hours and 13GB memory (100
iterations), while HiC-ACT only requires 7 minutes and 1.3GB memory using the suggested
initial p-value filter.
For the reasons presented here, we chose not to further compare HiC-ACT to FastHiC.
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Table A.1: Recommendations for selecting a HiC-ACT smoothing parameter (h) following the
HiCRep [142] method based on data resolution.






Table A.2: Recommendations for defining HiC-ACT peaks at various sequencing depths (in
approximate billions of raw reads). minCC is the minimum number of observed contact counts
and minEC is the minimum expected contact counts. Peaks are also required to have a ratio of
observed to expected contact counts of at least 1.5. Initial p filtering refers to which p-values are
to be considered for smoothing. The initial p filtering threshold was chosen through our simula-
tion studies such that the type I error was 0.05 when the global p threshold was 1e-12. The results
are robust to minor adjustments in the global p-value threshold, as shown in the precision recall
curves (Figure 2.2, Figures A.1-A.2). HiC-ACT can be made more conservative by choosing a
more stringent initial p filter.
Sequencing Depth (unit: billion) minCC minEC Initial p Filtering
0.5 5 .5 1.8e-2
1.0 5 1 1.7-4
1.5 5 1.5 4.9e-6
2.0 5 2 1.8e-7











































































































































































































































































































































































































































































































































































































































Table A.4: Comparing HiC-ACT and FitHiC peak calls with ChIP-seq and ATAC-seq peaks in
mESC data. The number of the 100k (A), 250k (B), 500k (C), and 750k (D)) most significant
HiC-ACT and FitHiC2 interactions which have each end overlapping with an enhancer mark or
promoter mark followed by the number of 1D overlaps between a 10Kb bin from most significant
HiC-ACT and FitHiC2 interactions and a ChIP-seq/ATAC-seq peak. The most significant HiC-
ACT-specific interactions show higher overlap with enhancer-promoter (E-P), enhancer-enhancer
(E-E), and promoter-promoter (P-P) interactions than the same number of most significant
FitHiC2-specific interactions. Odds ratio estimates and corresponding p-values for the proportion
of total HiC-ACT (HiC-ACT-specific + Shared) and total FitHiC2 (FitHiC2-specific + Shared)
most significant interactions overlapping an E-P, E-E, or P-P interaction out of the total number
of top peaks examined are reported. The odds of the most significant HiC-ACT peaks showing
overlap with E-P, E-E, or P-P interactions is significantly greater than the odds of the most signifi-
cant FitHiC2 peaks. We see similar results when only considering the 1D overlaps in H3K27ac,
H3K4me1, and H3K4me3 ChIP-seq peaks, and a comparable performance between HiC-ACT
and FitHiC2 in ATAC-seq peaks and CTCF ChIP-seq peaks.
A. Top 100k Peaks
HiC-ACT-specific FitHiC2-specific Shared OR Estimate p-value
Enhancer-Promoter 7,653 3,508 4,446 1.59 2.4e-210
Enhancer-Enhancer 7,366 4,123 4,808 1.41 1.6e-123
Promoter-Promoter 3,321 1,304 1,991 1.65 2.8e-110
CTCF 40,500 41,497 22,221 - -
H3K4me1 58,090 47,918 28,458 - -
H3K4me3 41,673 31,937 21,446 - -
H3K27ac 34,462 22,261 16,935 - -
ATAC 63,115 60,400 30,722 - -
B. Top 250k Peaks
HiC-ACT-specific FitHiC2-specific Shared OR Estimate p-value
Enhancer-Promoter 12,723 4,351 11,174 1.6 < 3.8e-271
Enhancer-Enhancer 12,077 5,293 11,632 1.44 3.8e-271
Promoter-Promoter 5,354 1,457 4,961 1.63 6.3e-208
CTCF 81,709 82,037 65,236 - -
H3K4me1 119,278 92,304 85,667 - -
H3K4me3 81,703 57,354 61,606 - -
H3K27ac 65,344 37,676 48,736 - -
ATAC 134,529 125,494 94,920 - -
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C. Top 500k Peaks
HiC-ACT-specific FitHiC2-specific Shared OR Estimate p-value
Enhancer-Promoter 13,603 3,943 20,684 1.42 < 2.4e-288
Enhancer-Enhancer 13,357 4,662 21,661 1.36 2.4e-288
Promoter-Promoter 5,454 1,449 8,755 1.4 4.7e-149
CTCF 119,254 113,388 156,336 - -
H3K4me1 174,257 122,681 205,120 - -
H3K4me3 111,723 71,162 139,261 - -
H3K27ac 87,284 45,221 106,722 - -
ATAC 208,023 185,826 237,686 - -
D. Top 750k Peaks
HiC-ACT-specific FitHiC2-specific Shared OR Estimate p-value
Enhancer-Promoter 12,071 3,860 27,776 1.27 8.9e-218
Enhancer-Enhancer 12,120 4,177 29,222 1.25 1.6e-195
Promoter-Promoter 4,711 1,584 11,555 1.24 7.8e-76
CTCF 131,698 121,595 255,400 - -
H3K4me1 192,246 126,146 335,221 - -
H3K4me3 117,364 70,952 217,335 - -
H3K27ac 90,146 44,743 163,132 - -
ATAC 240,532 210,032 404,924 - -
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APPENDIX B: ADDITIONAL RESULTS FOR CHAPTER 3
Figure B.1: Cell type-specifically expressed genes exhibit higher levels of chromatin interactivity
in the corresponding cell type. Each panel displays the empirical cumulative distribution function
(CDF) of the number of significant pcHi-C interactions for shared versus cell type-specific genes
in (a) erythrocytes, (b) macrophages/monocytes, (c) megakaryocytes, (d) naive CD4 T-cells, and
(e) neutrophils. The average number of interactions for specific and shared genes within each cell
type is reported along with the corresponding two-sided t-test p-value. (f) The number of specific
and shared genes per cell type.
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Figure B.2: A majority of SIPs are cell type-specific or shared across all five cell types. Details
of SIPs are shared across cell types (black). Most SIPs, however, are cell-type specific (blue) or
common between all five cell type groups (green).
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Figure B.3: Principal component analysis (PCA) on cumulative interaction scores reflects
expected correlations between SIPs. (a) PCA on the cumulative interaction scores of cell type-
specific SIPs shows most correlation between erythrocyte- and megakaryocyte-specific SIPS,
and distinction between those SIPs and the macrophage/monocyte-, naive CD4 T-cell- and
neutrophil-specific SIPs (all immune function-related cell types), reflecting known relationships
on the hematopoietic tree. (b) PCA on the cumulative interaction scores of SIPs, where “Shared”
refers to SIPs shared across all five cell types, and “Other” refers to a SIP in at least one cell type.
Figure B.4: PIRs of cell type-specific SIPs have greater odds of overlapping GWAS variants. In
each cell type, SIPs have greater odds of having at least one PIR overlap with a relevant GWAS
variant, compared to non-SIPs. Odds ratio estimates (purple dots) and corresponding 95% confi-
dence intervals are shown. The large confidence interval seen in macrophages/monocytes is due
to the relatively few number of cell type-specific SIPs.
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Figure B.5: Shared SIP genes have elevated expression levels in hematopoietic cell types. (a)-(b)
Shared SIP genes with the top 10% (a) or 10-20% (b) of expression among blood cells. (c)-
(d) Shared SIP genes with the top 10% (c) or 10-20% (d) of expression among other tissues
(non-blood cells). Figure B.5 continues on the following page.
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Figure B.6: Neutrophil specific SIP genes have elevated expression levels in neutrophils. The
cell type-specific SIP genes for erythrocytes, macrophages/monocytes, and naive CD4 T-cells
show similar trends. (a)-(b) Neutrophil-specific SIP genes with the top 10% (a) or 10-20% (b) of
neutrophils expression. (c)-(d) Neutrophil-specific SIP genes with the top 10% (c) or 10-20% (d)
of expression among other tissues (non-blood cells). Figure B.6 continues on the following page.
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Figure B.7: Partitioned SNP heritability for blood cell traits - cell type-specific SIPs. Enrichment
scores for cell type-specific SIPs and 15 blood cell traits. (˚ denotes statistically significant
enrichment score (p ă 0.05).
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Figure B.8: Partitioned SNP heritability for blood cell traits - all SIPs. Enrichment scores for
SIPs and 15 blood cell traits. (˚ denotes statistically significant enrichment score (p ă 0.05).
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Table B.1: Total counts of cell type-specific SIPs and SIP genes as well as total counts of all SIPs
and SIP genes, in each cell type. The total number of SIPs and SIP genes shared across all five




Erythrocyte 189 1,157 16.3%
Macrophage/Monocyte 107 808 13.2%
Megakaryocyte 302 1,287 23.4%
Naive CD4 T-cell 283 993 28.5%
Neutrophil 274 861 31.8%
Shared NA 170 NA
SIP Genes
#Specific #Total Percent
Erythrocyte 251 1,615 15.6%
Macrophage/Monocyte 125 1,093 11.4%
Megakaryocyte 385 1,752 22.0%
Naive CD4 T-cell 386 1,393 27.7%
Neutrophil 284 1,201 32.0%
Shared NA 234 NA
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Table B.2: SIPs interact with more super promoter-interacting regulatory regions (super PIRs)
than non-SIPs. Details corresponding to Figure 3.4. For each cell type, the number of promoter
baits interacting with a super PIR or typical PIR are reported, along with the corresponding
ratio and Chi-square p-value. Median PIR scores for each cell type and promoter bait type are
also reported, along with the corresponding Wilcoxon p-value for the difference in distribution
between SIPs and non-SIPs.
Table B.3: SIP PIRs overlap with ATAC-seq peak regions. Details corresponding to Figure 6. For
each cell type, the number of SIP PIRs and non-SIP PIRs that overlap with a cell type-specific
ATAC-seq peak region are reported, along with the corresponding ratio and Chi-square p-value.
The median (Med.) and average (Avg.) number of PIR interactions overlapping an ATAC-seq
peak and corresponding t-test p-value for the difference between SIP and non-SIP PIRs is also
reported. (Ovlp. = Overlap)
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Description of Supplemental Files
File S1. Details of SIPs and SIP genes. Each sheet in the Excel file details the SIPs and SIP
genes for each of the five cell types. The columns baitID, baitChr, baitStart, baitEnd, and bait-
Name pertain to the promoter bait identifier, gene(s), and bait location (from the Javierre et al.
[65] pcHi-C data). The column intscore refers to the cumulative interaction score calculated to
define SIPs, and the column rank reflects the order of SIP baits from largest score to smallest.
Note that a SIP bait may have multiple genes and genes may correspond to multiple SIP baits.
The column specific indicates if the SIP gene is only found in this particular cell type, and the
column shared indicates if the SIP gene is shared across all five cell types. The next five columns,
SIP.Ery, SIP.MacMon, SIP.MK, SIP.nCD4, and SIP.Neu, indicate whether that SIP is also found
in the respective cell type. The column ENSEMBL ID indicates the ENSEMBL ID (GRCh37),
if found, for the gene names (baitName) provided in the pcHi-C data. The subsequent columns
Ery, MacMon, MK, nCD4, and Neu, report the exponentiated BLUEPRINT gene expression
(equivalent to RPKM) data in that cell type, if available.
File S2. Details of SIP PIR overlap with GWAS Variants. Each sheet in the Excel file provides
information for the SIP PIRs that overlap with a relevant GWAS variant, for each of the five cell
types. The columns baitID, baitChr, baitStart, baitEnd, and baitName pertain to the promoter
bait identifier, gene(s), and bait location (from the Javierre et al.[65] pcHi-C data). The columns
oeStart, oeEnd, oeID, and oeName pertain to the other end (PIR) location, identifier, and gene(s).
The column specific indicates if the SIP gene is only found in this particular cell type (i.e., a cell
type-specific SIP). The remaining columns pertain to the GWAS variants: Phenotype, VariantID,
rsID, Position (hg19 base pair location of variant), pval, ancestry, and data (Vuckovic et al. [130]
or Chen et al. [19]).
File S3. Details of SIP Subnetworks. Each sheet in the Excel file details the SIP subnetworks
for a cell type and a particular phenotype. The naming convention for each sheet is “CellType Phenotype”.
A table of abbreviations and total SIP subnetworks for the cell type/phenotype combinations can
be found on the first sheet, “README”, along with column descriptions.
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APPENDIX C: ADDITIONAL RESULTS FOR CHAPTER 4
Figure C.1: Upset plot of selected AD/D variants. (AD/D = Altzheimer’s and other dementias;
BIP = bipolar; DEP = depression; SCZ = schizophrenia)
Figure C.2: Upset plot of selected BIP variants. (AD/D = Altzheimer’s and other dementias; BIP
= bipolar; DEP = depression; SCZ = schizophrenia)
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Figure C.3: Upset plot of selected DEP variants. (AD/D = Altzheimer’s and other dementias; BIP
= bipolar; DEP = depression; SCZ = schizophrenia)
Figure C.4: Upset plot of selected SCZ variants. (AD/D = Altzheimer’s and other dementias; BIP
= bipolar; DEP = depression; SCZ = schizophrenia)
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Figure C.5: Correlations between selected annotation features.
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Figure C.6: Box plots of annotation scores between simulated causal and non-causal variants.
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Table C.1: Genetic correlations between selected traits from LDSC regression analyses per-
formed by Bulik-Sullivan et al. [11]. (rg = estimate of genetic correlation; SE = standard error of
estimate)
Trait 1 Trait 2 rg SE p-value
Alzheimer’s Bipolar -0.011 0.0905 0.900
Alzheimer’s Depression 0.073 0.152 0.629
Alzheimer’s Schizophrenia 0.036 0.0646 0.581
Bipolar Depression 0.478 0.106 6.57e-6
Bipolar Schizophrenia 0.794 0.0386 7.45e-94
Depression Schizophrenia 0.508 0.0751 1.32e-11
Table C.2: Results of comparing ARVIN scores of selected variants to control variants. Wilcoxon
p-values and corresponding 95% confidence interval bounds for the difference between selected
and control variants are reported. For each trait, the averages were taken across the results from
each of the ten randomly sampled control variant sets.
Primary Trait Wilcoxon p-value Lower Bound Upper Bound
Bipolar 3.75e-5 0.0428 0.118
Depression 2.14e-11 0.135 0.269
Schizophrenia 7.4e-11 0.119 0.221
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